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Abstract 
 
Background: Visceral Leishmaniasis (VL) presents a major health problem 
in several states in Sudan. VL/HIV co-infection is an emerging health 
problem which has been reported to be associated with renal and liver 
dysfunction. 
Design: A descriptive study and cross sectional studies also were performed. 
Setting: The study was conducted at Tabarak-Allah Rural Hospital Gedarif 
state and Al- Azaza Centre, Sinnar State. 
Objectives:  
General objective: To study the prevalence of VL/HIV co-infection in the 
Sudan 
Specific objective:  To determine the liver and renal profiles in VL, HIV and 
VL/HIV co-infected patients. 
Material and methods: A total of 99 VL parasitologicaly confirmed cases 
in Tabarak-Allah Rural Hospital (Gedarif state, Eastern Sudan) and Al- 
Azaza Centre (Sinnar State) and. There were 57(57.6%) males and 
42(42.4%) females, their ages ranged from 2-75 years (mean of ages was 16 
years),30 HIV seropositive individuals from Al Gadarif Teaching Hospital 
were studied, 23 (76.7%) of them were males, and 7 (23.3%) were females. 
Their age ranged between 30 and 54 years (mean of age was 40 years). All 
serum samples from VL samples were analyzed for renal and liver profiles 
using chemistry analyzer and were also screened for HIV by third generation 
ELISA kits. The 30 HIV seropositive samples were analyzed for liver and 
renal profiles and for CD4 cell count by flowcytometry. 
Results: Of the 99 VL confirmed cases jaundice was detected in   Nine 
(9.1%), elevated AST activity in 85(85.9%), elevated ALT in  19(19.2%), 
VII 
 
elevated ALP in 55(556%) , low albumin level in 78(78.8%), 
hyperprotienamia in 40 (40.4%), azotamia in 7 (7.3%), hypocalcaemia in 48 
(48.5%), hyponatraemia in 89(899%), hypokalamia in 29(29.3%) and 
hyperkalaemia in 11(11.1%). Two (2.4%) patients had renal failure. 
Seven (7.1%)  of the 99  confirmed VL  patients were HIV co-infected. One 
(14.3%) of those 7 HIV/ VL co-infected cases had elevated ALT, 7(100%) 
had elevated AST, 6(85.7%) had elevated ALP activity, 2(28.6%) had 
hyperprotienamia, 5(71.4%) had hypoalbuminaemia, 3(42.9%) had 
hypocalcaemia, 7(100%) had hyponatraemia, 2(28.6%) had hypokalamia 
and 1(14.3%)  had hyperkalaemia. 
Of the 30  HIV seropositive individuals, 3(10%) were jaundiced,12(40%) 
had  elevated ALT,11(36.7%)  had elevated AST , 11(36.7%)  had elevated 
ALP, 6(20%) had hyperprotiemaemia,3(10%) had  hyperprotienamia, 
19(63.3%) had  hypoalbuminaemia, 3(10%)  had Azotamia, 16(60%)  had 
hyponatraemia, 2(6.7%)  had hyperkalaemia, 10(33.3%)  had hypokalamia, 
13(43.3%) had hyperuricaemia , 1(3.3%)  had hypouricaemia ,16(53.3%)  
had hypocalcaemia  and   one (3.3%) had renal failure. 
The comparison of liver profile between  confirmed  VL and VL/co-
infected cases showed significant differences in  in  ALT , ALP ,AST , 
T.Protien and Albumin Levels ( P.Value < 0.05) but there was   no 
significant difference in  T.Bilirubin and D.Bilirubin levels ( P.Value > 
0.05). In the renal profile creatinine and sodium levels, were also 
significantly different between the two groups (P.Value < 0.05). However, 
there was no significant difference in urea, calcium and potassium levels 
(P.value > 0.05).  
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Conclusion and Recommendation: In view of the results of the present 
study it is concluded that VL and VL/HIV co-infection can be associated 
with impairment in renal and liver functions; .The prevalence of VL /HIV 
co-infection is increasing in Sudan. Accordingly, it can be recommended 
that renal and liver profiles should be determined before treatment in all VL 
cases that show clinical features of renal or liver dysfunction. Urine analysis 
is recommended to be a routine test in VL as an indicator for any 
abnormality in renal function. Due to the limited number of VL/HIV co-
infected cases in the present study further studies involving larger sample 
size are required. 
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 اﻟﻣﺳــــ ــﺗﺧﻠص
ﺍﳌﺸﻜﻠﺔ  ﺍﻟﺼﺤﻴﺔ . ﺩﺍﺀ ﺍﻟﻠﺸﻤﺎﻧﻴﺎ ﺍﳊﺸﻮﻳﺔ ﳝﺜﻞ ﻣﺸﻜﻠﺔ ﺻﺤﻴﺔ ﻛﺒﲑﺓ ﰲ ﺍﻟﺴﻮﺩﺍﻥ ﻭﻏﲑﻫﺎ ﻣﻦ ﺍﻟﺪﻭﻝ ﺍﳌﻮﺑﺆﺓ : ﺍﳋﻠﻔﻴﺔ
ﺍﳋﻠﻞ ﺍﻟﻜﻠﻮﻱ . ﲔ ﻣﺮﺽ ﻧﻘﺺ ﺍﳌﻨﺎﻋﺔ ﺍﻟﺬﺍﺗﻴﺔ ﻭﺩﺍﺀ ﺍﻟﻠﺸﻤﺎﻧﻴﺎ ﺍﳊﺸﻮﻳﺔﺍﻟﻨﺎﺷﺌﺔ ﻫﻲ ﺣﺪﻭﺙ ﺯﻳﺎﺩﺓ ﰲ ﺍﻻﺻﺎﺑﺔ ﺍﳌﺸﺘﺮﻛﺔ  ﺑ
  .  ﲰﺔ ﻣﻦ ﺻﻔﺎﺕ ﻫﺬﺍ ﺍﳌﺮﺽ ﺍﺫ ﻳﺮﺗﺒﻂ ﺑﺎﻻﻋﺘﻼﻝ ﻭﳝﻜﻦ ﺍﻥ ﻳﺰﻳﺪ ﻣﻨﻪ ﻣﻌﺪﻝ ﺍﻟﻮﻓﻴﺎﺕ ﻭﺍﻟﻜﺒﺪﻱ ﳘﺎ
  .ﺍﺟﺮﻳﺖ ﺩﺭﺍﺳﺔ ﻭﺻﻔﻴﺔ ﻭﺩﺭﺍﺳﺔ ﻋﺮﺿﻴﺔ  ﻣﻌﺎ :ﻧﻮﻉ ﺍﻟﺪﺭﺍﺳﺔ 
ﻔﻲ ﺑﻮﻻﻳﺔ ﺍﻟﻘﻀﺎﺭﻑ ﻭﻣﺮﻛﺰ ﺻﺤﻲ ﺍﻟﻌﺰﺍﺯﺓ ﺩﺍﻣﻮﺱ ﻭﻻﻳﺔ ﺍﺟﺮﻳﺖ ﺍﻟﺪﺭﺍﺳﺔ ﰲ ﻣﺴﺘﺸﻔﻲ ﺗﺒﺎﺭﻙ ﺍﷲ ﺍﻟﺮﻳ :ﻣﻜﺎﻥ ﺍﻟﺪﺭﺍﺳﺔ 
  .ﺳﻨﺎﺭ 
  .ﺗﺎﻛﻴﺪ ﻣﻌﺪﻝ ﺍﻧﺘﺸﺎﺭ ﺍﻻﺻﺎﺑﺔ ﺍﳌﺸﺘﺮﻛﺔ ﺩﺭﺍﺳﺔ ﻭ : ﺍﳍﺪﻑ ﺍﻟﻌﺎﻡ  :ﺍﻻﻫﺪﺍﻑ 
ﻗﻴﺎﺱ ﻭﻇﺎﺋﻒ ﺍﻟﻜﺒﺪ ﻭﺍﻟﻜﻠﻲ ﰲ ﻣﺮﺿﻲ ﺩﺍﺀ ﺍﻟﻠﺸﻤﺎﻧﻴﺎ ﺍﳊﺸﻮﻳﺔ،ﻭ ﻣﺮﺽ ﻧﻘﺺ ﺍﳌﻨﺎﻋﺔ ﺍﻟﺬﺍﺗﻴﺔ، ﻭﻣﺮﺿﻲ : ﺍﳍﺪﻑ ﺍﳋﺎﺹ 
  .ﳌﻨﺎﻋﺔ ﺍﻟﺬﺍﺗﻴﺔ ﻭﺩﺍﺀ ﺍﻟﻠﺸﻤﺎﻧﻴﺎ ﺍﳊﺸﻮﻳﺔ ﺍﻻﺻﺎﺑﺔ ﺍﳌﺸﺘﺮﻛﺔ  ﺑﲔ ﻣﺮﺽ ﻧﻘﺺ ﺍ
ﺫﻛﻮﺭ  75ﻣﻨﻬﻢ  ﺣﺎﻟﺔ ﻣﺆﻛﺪﺓ ﻣﻦ ﺩﺍﺀ ﺍﻟﻠﺸﻤﺎﻧﻴﺎ ﺍﳊﺸﻮﻳﺔ ﰲ ﻫﺬﻩ ﺍﻟﺪﺭﺍﺳﺔ 99ﰎ ﺗﺴﺠﻴﻞ ﳎﻤﻮﻋﺔ  :ﺍﳌﻮﺍﺩﻭﺍﻻﺳﺎﻟﻴﺐ 
 03ﺑﺎﻻﺿﺎﻓﺔ ﺍﱄ ﺫﻟﻚ ﰎ ﺍﺩﺭﺍﺝ  ﻋﺎﻡ  61ﺳﻨﺔ ﻭﻣﺘﻮﺳﻂ ﺍﻟﻌﻤﺮ ﻟﺪﻳﻬﻢ  57-2ﻣﻦ ﺍﻻﻧﺎﺙ ﺗﺘﺮﺍﻭﺡ ﺍﻋﻤﺎﺭﻫﻢ ﺑﲔ  24ﻭ
ﻭﻣﺮﻛﺰ ﺻﺤﻲ ﺍﻟﻌﺰﺍﺯﺓ ﺩﺍﻣﻮﺱ ﻭﻻﻳﺔ  ﲑﻭﺱ ﻧﻘﺺ ﺍﳌﻨﺎﻋﺔ ﺍﻟﺬﺍﺗﻴﺔ ﻣﻦ ﻣﺴﺘﺸﻔﻲ ﺍﻟﻘﻀﺎﺭﻑ ﺍﻟﺘﻌﻠﻴﻤﻲﺷﺨﺼﺎ ﻣﺼﺎﺑﺎ ﲟﺮﺽ ﻓ
ﰎ ﲢﻠﻴﻞ .  ﻋﺎﻡ  04ﺳﻨﺔ ﻭﻣﺘﻮﺳﻂ ﺍﻟﻌﻤﺮ ﻟﺪﻳﻬﻢ  45-03ﻣﻦ ﺍﻻﻧﺎﺙ ﺗﺘﺮﺍﻭﺡ ﺍﻋﻤﺎﺭﻫﻢ ﺑﲔ  7ﺫﻛﻮﺭ ﻭ 32ﺳﻨﺎﺭ ﻣﻨﻬﻢ 
ﺎﺕ ﻟﻮﺟﻮﺩ ﻓﲑﻭﺱ ﻧﻘﺺ ﺍﳌﻨﺎﻋﺔ ﲨﻴﻊ ﺍﻟﻌﻴﻨﺎﺕ ﻟﻮﻇﺎﺋﻒ ﺍﻟﻜﻠﻲ ﻭﺍﻟﻜﺒﺪ ﺑﺎﺳﺘﺨﺪﺍﻡ ﳏﻠﻞ ﺍﻟﻜﻴﻤﻴﺎﺀ ﻛﻤﺎ ﰎ ﻓﺤﺺ ﻫﺬﻩ ﺍﻟﻌﻴﻨ
ﻭﻗﺪ ﰎ ﺍﻳﻀﺎ ﲢﻠﻴﻞ ﻋﻴﻨﺎﺕ ﺍﳌﺼﺎﺑﲔ ﺑﻔﲑﻭﺱ ﻧﻘﺺ ﺍﳌﻨﺎﻋﺔ ﻟﻮﻇﺎﺋﻒ ﺍﻟﻜﺒﺪ . ﺍﻟﺬﺍﺗﻴﺔ ﺑﻮﺍﺳﻄﺔ ﺍﳉﻴﻞ ﺍﻟﺜﺎﻟﺚ ﻣﻦ ﳏﺎﻟﻴﻞ ﺍﻻﻻﻳﺴﺎ 
  .ﻣﻄﻴﺎﻑ ﻗﻴﺎﺱ ﺍﳋﻼﻳﺎﺑﻮﺍﺳﻄﺔ ﺟﻬﺎﺯ ( 4DC)ﻭﺍﻟﻜﻠﻲ ﻭﺧﻼﻳﺎ ﺍﻟﻠﻤﻔﺎﻭﻳﺎﺕ ﺭﻗﻢ ﺍﺭﺑﻌﺔ 
ﺍﺭﺗﻔﺎﻉ % ( 1.9)ﻣﺮﺿﻲ ﺩﺍﺀ ﺍﻟﻠﺸﻤﺎﻧﻴﺎ ﺍﳊﺸﻮﻳﺔ ﺗﺴﻌﺔ ﻣﺼﺎﺑﲔ ﺑﺎﻟﲑﻗﺎﻥ ﺍﻇﻬﺮﺕ ﻧﺘﺎﺋﺞ ﻭﻇﺎﺋﻒ ﺍﻟﻜﻠﻲ ﻭﺍﻟﻜﺒﺪ ﰲ :ﺍﻟﻨﺘﺎﺋﺞ
ﰲ  PLAﺍﺭﺗﻔﺎﻉ ﻧﺸﺎﻁ ﺍﻧﺰﱘ %( 2.91) 91ﰲ  TLA، ﺍﺭﺗﻔﺎﻉ ﻧﺸﺎﻁ ﺍﻧﺰﱘ %( 9.58) 58  TSAﻧﺸﺎﻁ ﺍﻧﺰﱘ 
%( 4،04) 04ﺍﺭﺗﻔﺎﻉ ﻣﺴﺘﻮﻱ ﺍﻟﱪﻭﺗﲔ ﰲ ( 8,87)%ﺷﺨﺺ  87ﺍﳔﻔﺎﺽ ﻣﺴﺘﻮﻱ ﺍﻟﺰﻻﻝ ﰲ %( 6.55) 55
ﺷﺨﺺ  98ﻧﻘﺺ ﺻﻮﺩﻳﻮﻡ ﺍﻟﺪﻡ ﰲ %( 5،84) 84ﻧﻘﺺ ﺍﻟﻜﺎﻟﺴﻴﻮﻡ ﰲ ﺍﻟﺪﻡ ﰲ %( 3،7) 7ﻨﺎ ﰲ ﺍﺭﺗﻔﺎﻉ ﻣﻌﺪﻝ ﺍﻟﺒﻮﻟﻴ
 X
 
%( 4،2)ﻭﺍﺛﻨﺎﻥ %( 1،11) 11ﻭﺍﺭﺗﻔﺎﻉ ﺑﻮﺗﺎﺳﻴﻮﻡ ﺍﻟﺪﻡ ﰲ %( 3،92) 92ﻧﻘﺺ ﺑﻮﺗﺎﺳﻴﻮﻡ ﺍﻟﺪﻡ ﰲ %( 9،98)
  .ﻣﻨﻬﻢ ﻣﺼﺎﺑﲔ ﺑﺎﻟﻔﺸﻞ ﺍﻟﻜﻠﻮﻱ 
ﻭﻛﺎﻥ % 1.7( ﺇﺻﺎﺑﺔ ﻣﺸﺘﺮﻛﺔ)ﻨﺎﻋﺔ ﺍﻟﺬﺍﺗﻴﺔ  ﻣﺼﺎﺏ ﺑﺪﺍﺀ ﺍﻟﻠﺸﻤﺎﻧﻴﺎ ﻣﺼﺎﺑﲔ ﺑﻔﲑﻭﺱ ﻧﻘﺺ ﺍﳌ 99ﻭﻛﺎﻥ ﺳﺒﻌﺔ ﻣﻦ ﺍﺻﻞ 
 6،  TSAﻭﻛﻞ ﺍﳌﺮﺿﻲ ﻟﺪﻳﻬﻢ ﺍﺭﺗﻔﺎﻉ ﰲ ﻧﺸﺎﻁ ﺍﻧﺰﱘ  TLAﻣﻨﻬﻢ ﻟﺪﻳﻪ ﺍﺭﺗﻔﺎﻉ ﰲ ﻧﺸﺎﻁ ﺍﻧﺰﱘ %( 3.41)ﻭﺍﺣﺪ 
ﻧﻘﺺ %( 4.17) 5ﺍﺭﺗﻔﺎﻉ ﻣﺴﺘﻮﻱ ﺍﻟﱪﻭﺗﲔ ، %( 2.82)2،  PLAﻟﺪﻳﻬﻢ ﺍﺭﺗﻔﺎﻉ ﰲ ﻧﺸﺎﻁ ﺍﻧﺰﱘ %( 6.58)
%( 6.82) 2،%( 001)ﻴﻮﻡ ﺍﻟﺪﻡ ، ﻧﻘﺺ ﺍﻟﺼﻮﺩﻳﻮﻡ ﰲ ﻛﻞ ﺍﳌﺮﺿﻲ ﻧﻘﺺ ﻛﺎﻟﺴ%( 9.24) 3ﺍﻟﺰﻻﻝ ﰲ ﺍﻟﺪﻡ ، 
  .ﻟﺪﻳﻪ ﺯﻳﺎﺩﺓ ﰲ ﺑﻮﺗﺎﺳﻴﻮﻡ ﺍﻟﺪﻡ %( 3.41) 1ﻧﻘﺺ ﺑﻮﺗﺎﺳﻴﻮ ﺍﻟﺪﻡ ﻭﻫﻨﺎﻙ 
ﻟﺪﻳﻬﻢ ﺯﻳﺎﺩﺓ ﰲ ﻧﺸﺎﻁ ﺍﻧﺰﱘ %( 04) 21ﻣﺼﺎﺑﲔ ﺑﺎﻟﲑﻗﺎﻥ ، %( 01) 3ﰲ ﺍﳌﺮﺿﻲ ﺍﳌﺼﺎﺑﲔ ﺑﻔﲑﻭﺱ ﻧﻘﺺ ﺍﳌﻨﺎﻋﺔ 
  PLAﻟﺪﻳﻬﻢ ﺯﻳﺎﺩﺓ ﰲ ﻧﺸﺎﻁ ﺍﻧﺰﱘ %( 7.63) 11،  TSAﺰﱘ ﻟﺪﻳﻬﻢ ﺯﻳﺎﺩﺓ ﰲ ﻧﺸﺎﻁ ﺍﻧ%( 7.63) 11،  TLA
ﻟﺪﻳﻬﻢ ﺍﺭﺗﻔﺎﻉ ﻣﻌﺪﻝ %( 01) 3ﻧﻘﺺ ﺍﻟﺰﻻﻝ ﰲ ﺍﻟﺪﻡ ، %( 3.36) 91ﺍﺭﺗﻔﺎﻉ ﻣﺴﺘﻮﻱ ﺍﻟﱪﻭﺗﲔ ، %( 02) 6، 
ﻟﺪﻳﻬﻢ %( 3.33) 01ﺍﺭﺗﻔﺎﻉ ﺑﻮﺗﺎﺳﻴﻮﻡ ﺍﻟﺪﻡ ، %( 7.6) 2ﻧﻘﺺ ﺻﻮﺩﻳﻮﻡ ﺍﻟﺪﻡ ، %( 06) 61ﺍﻟﺒﻮﻟﻴﻨﺎ ﰲ ﺍﻟﺪﻡ ، 
ﻧﻘﺺ ﰲ ﲪﺾ ﺍﻟﻴﻮﺭﻳﻚ %( 3.3) 1ﻟﺪﻳﻬﻢ ﻓﺮﻁ ﰲ ﺣﺾ ﺍﻟﻴﻮﺭﻳﻚ ﰲ ﺍﻟﺪﻡ ، %( 3.34) 31،  ﻧﻘﺺ ﺑﻮﺗﺎﺳﻴﻮﻡ ﺍﻟﺪﻡ
  .ﻣﺼﺎﺏ ﺑﺎﻟﻔﺸﻞ ﺍﻟﻜﻠﻮﻱ%( 3.3)ﻟﺪﻳﻬﻢ ﻧﻘﺺ ﻛﺎﻟﺴﻴﻮﻡ ﺍﻟﺪﻭ ﻭﻭﺍﺣﺪ %( 3.35) 61ﰲ ﺍﻟﺪﻡ ، 
ﺃﻇﻬﺮﺕ ﺍﳌﻘﺎﺭﻧﺔ ﺑﲔ ﺩﺍﺀ ﺍﻟﻠﺸﻤﺎﻧﻴﺎ ﺍﳊﺸﻮﻳﺔ ﻭ ﺣﺎﻻﺕ ﺍﻻﺻﺎﺏ ﺍﳌﺸﺘﺮﻛﺔ ﻣﻊ ﻣﺮﺽ ﻧﻘﺺ ﺍﳌﻨﺎﻋﺔ ﺍﺧﺘﻼﻓﺎﺕ ﻛﺒﲑﺓ ﰲ 
ﺍﻣﺎ ﺍﺧﺘﺒﺎﺭﺍﺕ ﻭﻇﺎﺋﻒ ﺍﻟﻜﺒﺪ ﺍﻇﻬﺮﺕ ﺍﻳﻀﺎ ﺍﺣﺘﻼﻓﺎﺕ ﻛﺒﲑﺓ .  50.0 < eulav.P( ﺍﻟﻌﻤﺮ ﻭﺍﻟﻘﺒﻴﻠﺔ )ﻟﺒﻴﺎﻧﺎﺕ ﺍﻟﻮﺑﺎﺋﻴﺔ ﺍ
ﻭﻟﻜﻦ ﱂ ( 50.0 < eulav.P)ﻭﻣﺴﺘﻮﻳﺎﺕ ﺍﻟﺰﻻﻝ   TSA ,PLA , TLAﺑﲔ ﺍﻤﻮﻋﺘﲔ ﰲ ﻣﺴﺘﻮﻳﺎﺕ ﻧﺸﺎﻁ 
 ﺍﺧﺘﺒﺎﺭﺍﺕ ﻭﻇﺎﺋﻒ ﺍﻟﻜﻠﻲ ﻭﺟﺪ ﺍﻣﺎ ﰲ(.  50.0 > eulav.P)ﺍﻭﻳﺔ ﺮﻳﻜﻦ ﻫﻨﺎﻙ ﺍﺧﺘﻼﻑ ﻣﻠﺤﻮﻅ ﰲ ﻣﺴﺘﻮﻱ ﺍﻟﺼﻔ
ﻭﱂ ﻳﻜﻦ ﻫﻨﺎﻟﻚ ﺍﺧﺘﻼﻑ ( 50.0 < eulav.P)ﺍﺧﺘﻼﻑ ﻣﻠﺤﻮﻅ ﰲ ﻣﺴﺘﻮﻳﺎﺕ ﺍﻟﻜﺮﻳﺎﺗﻨﲔ ﻭﺍﻟﺼﻮﺩﻳﻮﻡ ﺑﲔ ﺍﻤﻮﻋﺘﲔ 
ﻫﺬﺍ ﻗﺪ ﻳﻜﻮﻥ ﺭﺍﺟﻌﺎ ﺇﱄ ﺍﻟﺘﺄﺧﺮ ﰲ (. 50.0 > eulav.P)ﻣﻠﺤﻮﻅ ﰲ ﻣﺴﺘﻮﻳﺎﺕ ﺍﻟﺒﻮﻟﻴﻨﺎ ،ﺍﻟﻜﺎﻟﺴﻴﻮﻡ ﻭﺍﻟﺒﻮﺗﺎﺳﻴﻮﻡ 
  . ﻧﺴﺠﺔﺍﻟﺘﺸﺨﻴﺺ ﺃﻭ ﺇﱄ ﺍﻟﻄﻔﻴﻞ ﰲ ﺗﻠﻚ ﺍﻷ
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ﻫﻮ ﻭﺍﺿﺢ ﺍﳋﻠﻞ ﺍﻟﻜﻠﻮﻱ ﻟﺪﻱ ﻣﺮﺿﻲ ﺩﺍﺀ ﺍﻟﻠﺸﻤﺎﻧﻴﺎ ﺍﳊﺸﻮﻳﺔ ، ﻭﺃﻛﺜﺮ ﺩﻋﻤﺎ ﻟﺮﺻﺪ ﻣﺪﻱ ﺷﺪﺓ  :ﺍﻹﺳﺘﻨﺘﺎﺝ ﻭﺍﻟﺘﻮﺻﻴﺔ 
ﺍﳌﺮﺽ ﻭﺍﻟﻌﻼﺝ ،ﻭﻭﻇﺎﺋﻒ ﺍﻟﻜﺒﺪ ﺃﻇﻬﺮﺕ ﺍﻳﻀﺎ ﺍﻟﲑﻗﺎﻥ ﻭﺍﻹﺭﺗﻔﺎﻉ ﺍﳌﻠﺤﻮﻅ ﰲ ﻧﺸﺎﻁ ﻛﻞ ﺇﻧﺰﳝﺎﺕ ﺍﻟﻜﺒﺪ ﰲ ﻣﺮﺿﻲ ﺩﺍﺀ 
  . ﻓﲑﻭﺱ ﻧﻘﺺ ﺍﳌﻨﺎﻋﺔ ﻭﺃﻳﻀﺎ ﻣﺮﺿﻲ ﺍﻹﺻﺎﺑﺔ ﺍﳌﺸﺘﺮﻛﺔ  ﺍﻟﻠﺸﻤﺎﻧﻴﺎ ﺍﳊﺸﻮﻳﺔ ﻭﻣﺮﺿﻲ
ﳝﻜﻦ ﺃﻥ . ﻭﺃﺻﺒﺢ ﻳﺸﻜﻞ ﻣﺸﻜﻠﺔ ﺻﺤﻴﺔ ﺧﻄﲑﺓ, ﻣﻌﺪﻝ ﺇﻧﺘﺸﺎﺭ ﻓﲑﻭﺱ ﻧﻘﺺ ﺍﳌﻨﺎﻋﺔ  ﰲ  ﺗﺰﺍﻳﺪ ﻣﻠﺤﻮﻅ ﰲ ﺍﻟﺴﻮﺩﺍﻥ 
ﻳﻜﻮﻥ ﺍﳌﻮﺻﻲ ﺑﻪ ﻭﺧﺎﺻﺔ ﰲ ﺣﺎﻻﺕ ﺍﻟﺼﺎﺑﺔ ﺑﺪﺍﺀ ﺍﻟﻠﺸﻤﺎﻧﻴﺎ ﺍﳊﺸﻮﻳﺔ ﻫﻮ ﺍﻟﺘﺤﻘﻴﻖ ﻣﻊ ﺍﻻﺷﺨﺎﺹ ﺍﻟﺬﻳﻦ ﺗﻈﻬﺮ ﻟﺪﻳﻬﻢ 
ﻳﻨﺼﺢ ﺍﻳﻀﺎ ﺑﺘﺤﻠﻴﻞ ﺍﻟﺒﻮﻝ ﻛﺈﺧﺘﺒﺎﺭ ﺭﻭﺗﻴﲏ ﻟﺪﻳﻬﻢ ﻭﺍﻟﺬﻱ ﻳﻌﺘﱪ ﻛﻤﺆﺷﺮ . ﺴﺮﻳﺮﻳﺔ ﻹﺣﺘﻼﻝ ﻭﻇﻴﻔﻲ ﰲ ﺍﻟﻜﻠﻲ ﺍﻷﻋﺮﺍﺽ ﺍﻟ
ﻛﻤﺎ ﳝﻜﻦ ﺍﻥ ﻳﻮﺻﻲ ﺑﻪ ﻭﺧﺎﺻﺔ ﰲ ﺣﺎﻻﺕ ﺩﺍﺀ ﺍﻟﺸﻤﺎﻧﻴﺎ ﺍﻟﺘﺤﻘﻴﻖ ﻣﻊ ﺍﻻﺷﺨﺎﺹ .ﻋﻠﻲ ﻭﺟﻮﺩ ﺍﻱ ﺧﻠﻞ ﰲ ﻭﻇﻴﻔﺔ ﺍﻟﻜﻠﻲ
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I. Introduction & Literature review 
 
1.1. Leishmaniasis Overview: 
Leishmaniasis is an infection caused by protozoan of the genus Leishmania 
of Trypanosomatidae family. The infection is transmitted by infected female sand 
flies of the genus Phlebotomous in the Old World and Lutzomyia in the New 
World. About 30 species of Leishmania are known to infect man leading to a wide 
clinical spectrum. These include three forms of leishmaniasis; namely the 
cutaneous (CL), the muco cutaneous (MCL) and the visceral leishmaniasis (VL) 
(WHO, 1990).  
About 35 million were believed to be at risk of having leishmaniasis in 
about 88 countries where as 12 million having been reported to be currently 
infected (Salotra et al., 2001). Without prompt appropriate treatment, as many as 
95% of kala-azar patients die, resulting in at least 50,000 deaths per year world-
wide (Kolaczinski et al., 2008). However the actual number of cases estimated to 
be three to five times higher than the number reported as leishmaniasis usually 
occurs in remote areas where other health problems are predominant (WHO, 
1993). 
The World Health Organization (WHO, 1990) recognized the disease as 
one of the most important parasitic diseases in the UNDP/World Bank/WHO 
Special Program for Research and Training in Tropical Diseases (TDR). VL 
affects at least 12 million people worldwide with an annual incidence of 500.000 
new cases (WHO, 1996). Previous epidemics of VL involving hundreds of 
thousands of people had occurred in India, Bangladesh and Sudan (WHO, 1996). 
The disease is fatal, with a mortality rate reaching approximately 100% among 
untreated cases (WHO, 1996). But some 95% recover if treated in time 
(IRIN,2009). 
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Of the 500,000 new cases of VL which are estimated to occur annually; 90% come 
from five countries Bangladesh, Brazil, India, Nepal and Sudan. VL is caused by 
L. donovani in the Indian subcontinent and in east Africa, by L. infantum in the 
Mediterranean region and by L Chagasi, which is closely related to L. infantum, in 
the new world mainly in Brazil, Peru and Paraguay (WHO, 1993). 
The disease results from multiplication of the parasites (Leishmania 
amastigotes) within the mononuclear phagocytes of the reticulo-endothial system 
.The classical clinical features of VL are fever,  weight loss, pancytopenia and on 
physical examination, hepatosplenomegaly with the spleen generally more 
enlarged than the liver , typically 5-15 cm below the left costal margin (WHO, 
1996). Splenomegaly may be absent in 5% of cases (Nandy, 1998).Malnutrition is 
an established risk for development of VL in childhood (Yousif, 1967). 
Histologically, the parasites may be found in the macrophage of the spleen, liver, 
lymph node and even the skin. Immunologically VL patients show a selective 
energy to Leishmania antigens, first characterized by a negative Leishmanin test, 
which may fail to convert even after cure (Elhassan et al., 2001). 
1.2. Historical background of VL: 
                    Kala-azar first came to the attention of Western doctors in 1824 in 
Jessore, India (now Bangladesh), where it was initially thought to be a form of 
malaria. Assam gave kala-azar one of its common names, Assam fever (Mosby’s 
Medical Dictionary, 2009).        
Visceral and cutaneous leishmanaisis were known as far back as the first 
century A.D in central Asia. VL has been known in the old world in India since the 
19th century by the name black fever or Kala-azar due to skin darkening. A 
mastigotes were first seen in the skin of a patient with "Delhi boil" in Calacuta by 
Cunningham in 1885 (WHO, 1984). William Leishman in 1903 was able to 
identify the organism in the splenic smear of an Indian patient who died "with 
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Dum Dum" fever, another name for VL. At the same year Donovan recognized the 
same intracellular parasite, seen by Leishman, in the spleens of three cases in 
Madras, who presented with fatal disease that was considered as chronic malaria. 
Hence the organism was named Leishman Donovan body in honour of these two 
pioneers in the field of leishmaniasis. Rogers in 1904 succeeded in culturing the 
parasite responsible for VL from splenic aspirates (Dedet et al., 1999). 
1.3. Epidemiology of VL: 
Leishmaniasis is a worldwide disease which is found in all continents, 
except Australia (Manson & Bahr, 1987). However it is most common in the 
tropics and sub-tropics. Certain factors contribute to determine its distribution such 
as high humidity and its mean diurnal variation (Napeir, 1946). There is a definite 
seasonal variation, most commonly in Autumn following rainy seasons, as in 
Bengal and , Endemic areas of kala-azar exist in the Sudan and these are confined 
to districts with a minimal annual rainfall of 10 inches; the disease does not occur 
in the northern arid areas of the Sudan. (Robert, Hasseeb. 1937) or in early summer 
as in China or in Spring as in Europe .VL is found in Asia , Southern Europe, 
particularly in Greece, Southern France, Spain. In South America it is found in 
Brazil and Venezuela. In Africa, the disease is found in Sudan, Ethiopia, Somalia, 
northern Kenya, Equatorial West Africa, Morocco, Algeria and Tunisia, (Manson 
& Bahr, 1987). 
1.4. Parasites of VL: 
Leishmaniasis is caused by protozoan parasites of the genus Leishmania 
which belongs to the family Trypansomatidae. It has different species which are 
responsible for the three clinico-pathological conditions; (a)Visceral leishmaniasis 
which is caused by L. donovani  complex (b) cutaneous-leishmaniasis caused by L. 
tropic , L. major, and  L. mexicana and (c) muco cutaneous Leishmaniasis which is 
caused by L. braziliensis and L.mexicana complexes (WHO, 1990). The L. 
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donovani complex has three subspecies L. donovani donovani (Sudan, India), L. 
donovani infantum (Mediteranian) and L.donovani chagasi (South America) 
(WHO, 1990). Infection with L. donovani occurs in three clinico epidemiological 
patterns which are Mediterranean type or infantile VL, Indian type VL and African 
type.  
The Leishmania parasites assume two forms, the flagellated form (infective 
stage) named promastigote and the non-flagellated form (amastigote). The 
promastigote form is 15-30 um long found in the gut of the sand fly (the vector) 
and can be cultivated in culture media. It has a single flagellum, arising from a 
blepharoplast at the anterior end and a nucleus. A mastigote is the intracellular 
form which is oval or round measuring about 2-3, um in length (Manosn & Bahr, 
1987). It is  found in the mammalian host and can be recovered from all 
endothelial cells, including reticulo endothelial system, bone marrow, lymph 
nodes, spleen and liver, as well as from monocytes, polymorphs and the sub-
mucosa of the respiratory and alimentary tracts (Napier, 1946). It can also be 
recovered from stool or urine (WHO, 1997). 
1.5. Life Cycle: 
L.donovani is an obligatory intracellular parasite which cycles between the 
mid gut of sand flies (extracellular promastigotes) and the phagolysosome of 
mammalian macrophages (intracellular amastigotes) (Dedet et al., 1999). 
Following inoculation of promastigotes into the skin of mammalian host by a sand 
fly (Phelebotomns orientalis) while seeking a blood meal at night, they soon lose 
their flagella, transform into the amastigote form and become engulfed by 
macrophages. Inside the macrophage they multiply by binary fission. The 
macrophage eventually ruptures when heavily parasitized to release parasites 
which are engulfed again by other new macrophages. The new amastigotes 
penetrate the cell membrane and are ingested by the sandfly, when it seeks its next 
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blood meal at night (Cheesbrough, 1995). Then each amastigote regains its 
flagellum, after going through many development stages. The sandfly becomes 
infectious within 10-15 days of the blood meal (Manson & Bahar, 1987). 
1.6. Reservoir hosts: 
There are two types of reservoir hosts: wild reservoirs such as canines 
which include foxes, wolves and jackal and domestic animals like dogs, rodents 
and rats (WHO, 1990).  
1.7. Vectors and transmission: 
VL is transmitted from one mammalian host to another including man by 
the female sand fly which has different species, geographical and seasonal 
distribution. Sandflies are mainly in the tropics and sub-tropics. In the following 
countries, the most common species include: in Sudan Phlebotomus papatasi (7%) 
and P. orientalis (5%) were sympatric, mainly inside homes (85% and 75%, 
respectively ( Dereure, El-safi, et al.2003) , P. martins in Kenya, P. major and P. 
pernicious in the Mediterranean, P. chinensis in China and P. argentipes in India.  
Other modes of transmission do exist although their occurrence is rare. 
These include blood transfusion, direct contact with blood, mucous, stools or nasal 
discharge (Manson & Bahr, 1987). Occasionally infection may occur accidentally 
in the laboratory (Terry, 1949; Manson & Bahr, 1987), or experimentally through 
injection of L. donovani intradermally that can produce nodules containing 
amastigotes (Manson & Bahr, 1962, 1987). Congenital transmission has been 
reported (Manson & Bahr, 1987) as well as sexual transmission (Symmers, 1960; 
Manson & Bahr, 1987). 
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1.8. Immunology: 
Leishmania a mastigotes produce variable effects on the elements of the 
immune system (WHO, 1990) Leading to variable host responses and producing a 
wide spectrum of disease (Manson & Bahr, 1995). 
Infection  with Leishmania donovani results in the development of organ-
specific immunity in the two main target tissues of infection, the spleen and the 
liver. The liver is the site of an acute resolving infection associated with the 
development of inflammatory granulomas around infected Kupffer cells, and 
resistance to reinfection. Paradoxically, the spleen is an initial site for the 
generation of cell-mediated immune responses, but ultimately becomes a site of 
parasite persistence with associated immunopathological changes (Stanley, 
Engwerda2007). 
Immunity against leishmania parasite is mediated by cellular mechanisms 
(Ghalib, 1993). Antibodies have little if any protective role against this organism 
(Probst et al., 2001); thus making the strategies of the host defense depend on the 
sequence of the reactions inside the macrophage. 
The organism protects itself by an electron dense material, thus it resists 
macrophage killing by oxygen dependent or non oxygen dependent mechanism 
due to oxidative metabolites that interfere with the activity of the lysosomal 
enzymes. Therefore macrophage microbicidal activity is reduced (Hoover et al., 
1985). 
The parasite produces modulation of the T-cell response. There is marked 
depression of the cell-mediated immunity, depressed delayed type hypersensitivity 
and low numbers of T-lymphocytes in active VL cases, which are reversible with 
successful treatment (Aikat et al., 1979, Ghose et al., 1979). When CD4 T-cell is 
activated, the outcome depends on the balance between T.hl/T. h2 responses 
(Sundar et al., 1997; Probst et al., 2001). This balance is thought to be genetically 
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determined which is important in the pathogenicity of the disease. Resistance and 
elimination of the parasite is in favour of the response which mediates the 
production of INF.λ and IL-2. T h2 response which involves the secretion of IL-4, 
1L-5, IL-6 and IL-10 is associated with disease susceptibility. IL-10 down 
regulates the T. h1 response (Ghalib et al., 1993). IL-15 is not functioning as a 
universal NK cell priming signal and that IL-18 contributes to the NK cell response 
in visceral leishmaniasis (Haeberein et al. 2010). 
Assessment of cell mediated immunity can be done by either in vitro or in 
vivo tests. The in vitro tests are lymphocyte proliferative, response and phenotypic 
distribution of the peripheral mononuclear cells (PMNC). Usually there is failure 
of lymphocytes to respond to leishmamal Ag as well as mitogens, 
phytohaemagyhitin and concavalin A, which are reversible with successful 
treatment (Ghose et al., 1979). Peripheral mononuclear cells fail to respond to 
leishmanial antigen, in active KA, as well as PKDL (El-Hassan et al., 1992), as 
compared to the cutaneous form. The response is specific to leishmanial antigen as 
it reverts to normal with commencement of therapy in vivo.  
Regarding the humoral immune responses there is marked increase 
imnmunoglobulin G (IgG) compared to immuno globulin M (IgM) (Manson & 
Bahr, 1987; Mure's, 1997). IgGI and IgG3 (sub-classes of IgG) are very specific 
and correlated with the disease activity as they decrease after treatment (EL-Assad 
et al., 1994). 
1.9. Pathology and pathogenicity of Kala-azar: 
After the host is bitten by an infected sandfly, the parasites disseminate in 
the blood stream and enter macrophages of the spleen, liver, bone marrow, lymph-
nodes, skin and small intestine. The promastigotes immediately lose their flagella 
and change their shape into the amastigote forms which attach themselves to the 
membrane of the macrophage and invade it. They spread from local lymph nodes 
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through the blood to different organs e.g. liver, spleen, bone marrow and lymph 
glands, rarely the intestine, adrenals, kidneys and lungs. A leishmanoma is formed 
in the skin after injection of the mammalian host with the promastigotes which 
may pass unrecognized.  
The pathology of leishmaniasis varies and is determined by factors such as 
the environment, the insect vector, and parasite and host genetics. 
(Sakthianandswaren et al., 2009)  
Usually there is anaemia which is commonly normocytic normochromic, 
sometimes thrompocytopenia and leucopenia occur which predispose the patient to 
secondary infection and haemorrhagic manifestations. (Nandy et al.,1998) reported 
a case presenting with renal haemorrage. Pancytopenia might result from 
hypersplenism or bone marrow involvement. 
The skin is commonly involved in kala -azar. In fatal cases all the skin layers are 
loaded with the parasite. In post kala-azar dermal leishmaniasis (PKDL), some of 
the parasites survive for a long time multiplying slowly in the skin.Other affected 
sites include the mucosa of the nasopharynx and oral cavity (El Hassan et al., 
1995), which make the diagnosis of Kalazar difficult. PKDL patients may be an 
important source of infection in VL transmission (Zijistra & El Hassn, 2001). 
Histocytic proliferation in these organs produces enlargement with atrophy 
or replacement of the normal tissue, therefore kala-azar is a systemic 
granulomatous disease of the reticulo-endothelial system (Manson & Bahr, 1987). 
1.10. Clinical Presentation: 
The natural history of the disease is progressive and it is fatal unless 
treated. The incubation period is variable, normally between 3-6 months (Hommel 
& Ashford, 1983). It can be as short as 10 days and as long as 10 years. The 
disease can affect younger age groups especially in the Mediterranean area (Less 
than 5 years) and East Africa (between 5-9 years). Males are more affected than 
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females with a ratio of 4:1 (Manson & Bahr., 1987). The disease can be endemic, 
sporadic or epidemic (WHO, 1990). The disease can be sub-clinical or 
asymptomatic (Napier., 1946; Manson & Bahr., 1987). The disease can presents 
with 3 clinical forms: 
l. A primary leishmanoma which is a small papule appearing 4-6 months before 
the onset of the disease or may go unnoticed (Manson & Bahr., 1987). 
2. An acute onset occurs either in sporadic or epidemic forms in non- 
immune people visiting an endemic area. 
3. Chronic form which is the most common presentation in 3 endemic areas. 
The patient presents with general ill health and cachexia (Cole, 1944 and 
Manson & Bahr, 1987). Fever is almost invariable, it can be high remittent with 
double peaks and associated with drenching sweating, but no rigors (Manson & 
Bahr, 1987); however, it can pass unnoticed by the patient. It may be intermittent 
or continuous in the established disease and may be absent in some cases (Napier, 
1946). Fever is accompanied by progressive splenomegaly which may be very 
huge in size, reaching the right iliac fossa within a few days (Manson & Bhar, 
1987). In a few cases the spleen is not palapable. Hepatomegaly is not to the same 
degree as splenomegaly. There may be cirrhosis, ascites or jaundice as a late 
complication of the disease. Diarrhoea may be one of the presenting symptoms due 
to gastro intestinal involvement, as well as epistaxis. Hyperpigmentation involves 
the hands, feet and abdomen (Napier, 1946). The lymph nodes are enlarged, 
especially in African kala azar. 
There may be mild cough and proteinuria, (Manson & Bahr, 1987) and 
oedema (Napier, 1946). Amyloidosis is a recognized complication and may regress 
with cure. Manson & Bahr, (1987) reported a patient who presented with tremors. 
Other neurological involvements like delerium and confusional states have also 
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been reported (Manson & Bahr, 1987). Retinal haemorrage is one of the presenting 
features of the disease.  
Mucosal and mucocutaneous involvement occurs sporadically in the Sudan 
and Eastern Africa. Complications are important causes of death, these include: 
tuberculosis, lobar pneumonia, dysentery, liver cirrhosis and cancrum oris 
(Manson & Bahr, 1987). 
1.11. Hematological Features of VL: 
Anaemia is invariable, especially in children and it is usually normocytic 
normochromic (Zijistra & El Hassan, 2001), it may be due to hyper-splenism, auto-
immunity with haemolysis or due to ineffective erythropoiesis. Leukopenia is 
marked and late in the disease. The total white blood cell count (TWBC) may 
reach levels below 2000/µl, and there may even be agranulocytosis in fatal cases. 
Thrombocytopenia and pancytopenia were reported above. The erythrocyte 
sedimentation rate (ESR) may reach a very high level. 
The haematological manifestations were reviewed in 94 patients (55 males 
and 39 females) with visceral leislimaniasis by (Nasir, A.M. et al 1995) in Saudi 
Arabia. They found that all patients had splenomegaly and were anaemic, while 
(73) were neutropenic and (56%) thrombocytopenic. Coagulation abnormalities 
were encountered in 10(11 per cent) patients; in four patients this was associated 
with disseminated intravascular coagulopathy. Bone marrow was hypercellular in 
(90%), normocellular in (5%), and hypocellular in (4%). Also variable degrees of 
erythrophagocytosis and leukophagocytos were noted with preponderance of 
histiocytes (46%) and granulomatous formation (25%). Low haemosiderin content 
in the bone marrow was noted, which together with the finding of high serum 
ferritin is consistent with anaemia of chronic inflammation. 
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1-12: Biochemical changes of Visceral Leishmaniasis: 
Renal dysfunction is an important feature of this disease; it is associated 
with important morbidity and can increase mortality. (Daher et al., 2008)  
 Renal changes consisted of the following : Glomerular lesions as segmental 
collapse of capillary loops, congestion of capillaries filled by Leishmanias , 
capsular synechiae, focal and segmental areas of glomerular sclerosis, focal 
thickening of basement membranes, parasite invasion of mesangial axes (cells and 
matrix) and focal mesangial and epithelial cell hyperplasia with initial crescent 
formation. Immunohystochemical examination was negative for immunoglobulins 
and light chains. Tubulo-interstitial damage as acute necrotizing tubulitis, tubular 
necrosis and hyaline casts, focal infiltration of CD68 and CD3 cells, and 
Leishmania inside of histiocytes in peritubular areas (Pintado et.al., 2001). Blood 
vessel changes: as focal leukocytoclastic vasculitis of vasa recta and free 
Leishmanias in the capillary lumina. Acute glomerulonephritis (GN), proliferative 
GN, collapsing focal segmental glomerulosclerosis, acute interstitial nephritis and 
tubular cell necrosis and tubulitis have all been described in patients with 
Leishmaniasis(Pintado et.al., 2001). In study carried about the disturbances in 
function of the tubules in human Kala-azar the principal alterations were 
hyponatremia 94.6%, hypokalemia 26%, hypochloremia 27.2%, hypocalcemia 
32%, hypomagnesemia 41.8%, hypouricemia 14.3%, Increased urinary excretion 
fraction were: sodium 15%, potassium 26%, chloride 33.3%, calcium 32%, 
inorganic phosphate 27.2%, magnesium 100% ( hypermagnesiuria), uric acid 44%. 
Glucosuria was found in one third of patients. There was evidence of renal 
proximal tubular damage with alterations in the reabsorption of proteins and light 
chains with characteristics of a tubular proteinuria, Disturbances of tubular 
reabsorption of uric acid, calcium, phosphate, glucose and magnesium were also 
observe (Agenor Araujo Lima et al., 2009) The renal damage in patient was 
12 
 
mediated through different mechanisms. Tubular necrosis was secondary to 
ischaemia, due to small vessel obliteration by Leishmanias, and to haemolysis. 
Necrotizing tubulitis was due to direct invasion by the parasites and by 
inflammatory reaction. There was a diffuse invasion of renal structures by 
Leishmania (Pintado et.al., 2001). 
In study carried in the Department of Nephrology and Kala-azar unit of 
Institute of Medical Sciences, Banaras Hindu University, Varanasi, India between 
April 2002 to May 2004, the renal involvement was documented in  (15%) cases. 
The spectrum of renal disease included; proteinuria in the range of 1-2gm/day 
(15%), abnormal urinary sediment (4%), and acute renal failure (15%) of cases. 
Dialytic support was not needed (Prakash et al.,2007)  
In Italy , (Rollino et al.,2003) reported a renal failure in 28- years old  
VL/HIV infected Nigerian woman who had been in Italy for 8 months, attended 
the hospital because of epistaxis, confusion and anuria. Her temperature was 
36.3°C, O2 saturation 98%, blood pressure 120/70 mmHg and cardiac pulse 
125/min. Her physical examination was unremarkable, except for abdominal 
tenderness. Laboratory investigations disclosed: HIV positivity, serum creatinine 
20.7 mg/dl, Na 140 mEq/l, K 7.5 mEq/l, Hb 7.9 g/dl, MCV 74 fl, WBC 4050/mm3, 
platelets 557 000/mm3, AST 424 U/l, ALT 41 U/l, bilirubin 3.6 mg/dl (3.4 mg/dl 
indirect), CPK 55 U/l, LDH 8096 U/l. There for dialysis was initiated. Light 
microscopy examination evidenced striking diffusion of Leishmanias in phagocytic 
cells and extracellular presence in vascular lumina and connective tissues (kidney, 
liver, nasopharynx, lung, skin, uterus, ovary, lymph nodes, bone marrow, heart and 
spleen). 
They concluded that, Leishmania behaves as an opportunistic infection in 
HIV-infected individuals. It should be suspected in African people in a case of 
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acute renal failure, when no other causes can be advocated. ARF can be due to 
direct invasion of parenchyma and to tubulo-interstitial and glomerular structures 
involvement (Pintado et.al, 2001). 
Also A 29-year-old full-term pregnant woman from a rural area of Iran, the 
Pars province, presented with fever of 2 months' duration. On physical 
examination, the only positive finding was a high temperature of 39.5°C. Due to a 
protruded abdomen, the liver and spleen could not be palpated. The clinical 
workup determined only the presence of anemia. On the second day after 
admission, the patient and fetus died. Autopsy revealed surprisingly numerous 
Leishman bodies in most organs, including the liver, spleen, bone marrow, adrenal, 
placenta, and kidney. In addition to increased numbers of Leishman bodies, the 
autopsy also revealed extensive centrilobular necrosis of the liver, severe 
congestion and white pulp depletion of the spleen, severe pulmonary congestion 
and edema, bilateral hemorrhagic necrosis of adrenals, and mesangioproliferative 
glomerulonephritis. They report the presence of typical Leishman bodies inside the 
mesangial cells of the glomerulus (Daneshbod et. al,1972). 
Also in Sudan LFT done for VL patients during an outbreak in white Nile 
province and they report presence of jaundice, hypoalbuminaemia, 
hyperglobulinaemia and elevation of liver enzymes (AST, ALT and ALP) 
(Mustafa 1995).  
1.13. Diagnosis of VL: 
There are three main diagnostic approaches for the confirmation of 
Kalazar. These include the parasitological, immunological and DNA based 
detection methods. 
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1.13.1. Parasitological diagnosis: 
1.13.1.1. Direct microscopy: 
The definitive and routine diagnosis of VL leishmaniasis relies on 
microscopic detection of leishman donovan bodies in Giemsa stained smears of 
lymph node, bone marrow or splenic aspirates (Evans, 1989). These methods are 
relatively simple and cheap but there is no possibility to distinguish between 
Leishmania amastigotes spp (Evans, 1989); while some of them lack sensitivity 
,others are invasive . Although spleenic aspiration is generally accepted as the most 
sensitive method and can detect more than 90% of cases (Manson & Bahr, 1987), 
it is contra - indicated because bleeding complications are feared. At least three 
separate studies showed a sensitivity of at least 94% for splenic puncture in VL 
patients (Siddig et al., 1988; Zijistra et al., 1992). Bone marrow aspiration unlike 
splenic aspiration or lymph node aspiration is often resented by the patient because 
it is painful especially in children. Microscopy of lymph node aspirates is the most 
commonly used procedure in endemic areas of Kala-azar in the Sudan as it is a safe 
and simple procedure (Siddig et al., 1988). However, a variable sensitivity was 
reported ranging from 58.3% (Zijistra et al., 1992) to 100% (Kirk and Satti, 1940). 
Liver aspiration is used infrequently in the diagnosis of VL (Zijistra et al., 1992). 
In HIV/ Lieshmania co-infected patients the amastigotes are found in the 
peripheral blood in 50% of cases and may be found in unusual location such as the 
lungs, larynx, gastro intestinal tract and C.S.F. (Manson & Bahr., 1987). 
1.13.1.2. In vitro culture of visceral leishmania: 
Culture of Leishmania parasites for diagnosis of leishmanasis has been 
used since the beginning of 20th century. Several culture media have been used 
including NNN and various semi-synthetic media, supplemented with blood or 
serum (Evans, 1989). For primary isolation of Leishmania parasites, small inocula 
of clinical material (lymph node, bone marrow, spleen aspirates ) is inoculated 
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under aseptic condition into the liquid phase of blood agar biphasic media, . The 
inoculated media are incubated at 24±2°c for 7-20 days using cooled incubator. 
Growth in culture tubes was detected by turbidity in the liquid phase of the media 
and confirmed microscopically by presence of motile promstigotes in smear 
preparations (WHO, 1996). 
Culture media for mass cultivation and primary isolation of old and new 
world forms of Leishmania spp include blood agar biphasic medium e.g NNN 
medium, sloppy Evans medium, semi solid Lockes blood agar, Evans modified 
Tobies medium Usmaru ( Difco BA) MEM: FCS: EBLB medium and Schneider's 
Drosophila medium (Evans., 1989). The organisms from patients with VL can be 
very difficult to cultivate (Evans, 1989). Therefore it is wise whenever possible to 
inoculate experimental animal as well. In attempt to cultivate Leishmania, it is 
advisable to use blood agar biphasic media preferably e.g NNN or USAMRU or 
modified Tobies medium but even when the initial isolation is successful the 
organism may die when sub-cultured. This seems to be especially common when 
the initial isolation has been into rich media such as USMARU or modified Tobies. 
Often this can be overcome if sub-cultures are made into less nutritionally rich 
media such as NNN or one of the semi solid media like sloppy Evans and semi 
solid Locke's blood agar (Evans., 1989& WHO., 1990). The variations of these 
media lead to efficacy in the transformation of amastigotes to promastigotes and in 
the growth rate of promastigotes. While being easy to carry out, Leishmania 
culture needs some expertise and sterile conditions during collection and 
processing of material from patients lesion or organs, and for sub culturing (Dedet 
et al., 1999). 
The purposes of culture of the genus leishmania include: accurate 
identification of the organism, to obtain a rich yield of the organism to be used as 
antigen in immunological diagnosis for teaching purposes, as a source for 
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inoculating susceptible experimental animals, for in vitro screening of drugs and 
for investigation of the physiology of the pathogens (Cheesbrough, 1995). Initial 
isolation is the process by which leishmania organisms are removed from their 
host and transferred either to an experimental animal (invivo isolation) eg hamester 
or into culture media (in vitro isolation) so that multiplication and bulk cultivation 
of leishmania is necessary for isoenzyme identification methods which require 
relatively a large number of promastigotes. The choice of isolation methods 
depends on the immediate circumstances and to some extent on the technical 
capabilities and experience of the staff. In-vitro isolation offers certain advantages 
over the in vivo methods as cultures become more rapidly positive after as a short 
time as 5-7 days in contrast to a week or a month required for a lesion to appear in 
an animal after inoculation the culture materials are less expensive and cultured 
organisms can be cryopreserved thus reducing the time and personnel required for 
its maintenance. The disadvantages of in-vitro culture are that some strains of 
leishmania donovani are extremely difficult to attain in the field (Evans, 1989). In 
vitro cultivation is an efficient method for the parasitological diagnosis of 
leishmaniasis and for distinguishing between various strains causing leishmaniasis. 
The most difficult part is usually the initial establishment of the organism in 
culture when the a mastigotes have to transform to promastigotes to begin 
multiplication and this step needs skills and technical capabilities as well as 
abilities in preparation specification and sterility during inoculation of the clinical 
samples into the different types of media . 
1.13.1.3. Animal inoculation (in vivo propagation): 
Hamster is considered to be a suitable model for propagation of Leishmania 
(Evans, 1989). The animal is inoculated intradermally or subcutaneously as well as 
in the nose and hind feet. A positive reaction is identified by finding an indurations 
or an ulcer at the injection site. The presence of amastigotes can be verified by the 
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examination of stained smears. Other animals like guinea pigs and inbred mice can 
be used (WHO, 1996). Usually laboratory animal inoculation is slower than culture 
methods. It takes 3-4 weeks for lesions to appear in contrast to the culture which 
takes 10-15 days for the development of the promastigotes (Evans, 1989). Previous 
investigations by (Satti et al 1958) also demonstrated that the grey monkey 
(Cercopithecus sebaezis ) and the red monkey (Cercopithecns ruler) has 
successfully became infected with L. donovani parasites. The method however, 
was criticized for being time consuming, laborious and unsuitable for routine 
diagnosis. 
1.13.2. Immunological diagnosis: 
Immunodiagnosis is of paramount importance in the diagnosis, follow up 
and control of infections .It can be divided into two parts: one which detects and 
measures antibodies in the serum and the other which can demonstrate or detect the 
cell mediated response (Bray, 1985; Lakshams, 1985). Immune-diagnosis is 
needed for rapid and reliable detection of early cases especially in the field when 
the parasite load is scanty and may not be revealed in smears. However it’s main 
problem is cross reactions. At present several immunological techniques based on 
cellular or humoral responses are widely used for the diagnosis of VL. 
1.13.2.1. Leishmanin skin test (L.S.T or Montenegro test): 
This test is a delayed type hypersensitivity reaction to Leishmania 
anologous to tuberculin and lepromin tests (Cheesbrough, 1995). The antigen 
consists of a suspension of killed promastigotes. The test is performed by 
intradermal injection of 0.1 ml phenolized antigen into one forearm and 0.1 ml 
phenol saline into the other forearm (Bray, 1976). The test is usually read after 48-
72 hours (Zuckerman, 1975 Bray, 1976) A positive reaction is indicated by a raised 
induration more than 5mm accompanied by erythema (Manson & Bahar, 1987). 
The test is not of diagnostic value in VL, but can help in epidemiological surveys 
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of past and subclinical infection in endemic areas as well as in the exclusion of 
active VL (Manson & Bahar, 1987, Zijistra et al 1993 and El Hassan et al 1993) 
showed that a positive LST indicates that a treated VL patient has developed cell 
mediated immunity to Leishmania. LST is positive in active and past infection of 
cutaneous leishmaniasis for life (Manson & Bahar, 1987). 
1.13.2.2. Non Specific Tests: 
The nonspecific reactions depend upon the increase of the immunoglobulin 
seen in Kalazar. It can be demonstrated by flocculation or precipitation 
(Zuckerman, 1975). The best examples are: 
1.13.2.2a Formal gel test (Napier aldehyde test): 
This test is performed by mixing 1 ml of serum with 2 drops of 30% 
formalin. The reaction is read after 20 minutes. A positive reaction is indicated by 
whitening and jelly appearance which indicate hyper globulinaemia (Ghose, 1980). 
The test is positive after 1-2 months of the infection and becomes negative after 6 
months of cure. It is simple easy to perform and cheaper therefore it is suitable for 
sero-epidemiological survey (Jalil et al., 1992). Sensitivity of this test is 62.7%and 
specificity is 93.2% (R. Kumar et al., 2006).It has a diagnostic value in chronic 
cases of kala- azar (Sen Gupta et al., 1969).The main disadvantage is the cross 
reactivity with other diseases that cause hyperglobulinaemia e.g leprosy, TB, 
trypansomiasis and schistosomiasis. 
1.13.2.2b Antimony (chopra test) or urea stibamine test: 
This test is used in India. The serum is diluted 1 in 10 with distilled water 
and placed in a narrow bore test tube then 4% urea stibamine solutions added and 
mixed gently. A positive reaction is indicated by flocculent precipitate after 10-15 
minutes. It is heavy in strong positive reaction (Manson & Bahar, 1987). 
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1.13.3. Specific tests: 
Various tests have been applied to detect specific anti leishmanial 
antibodies. These include DAT, ELISA, IFAT, CFT (Bray, 1985). Recently DAT, 
IFAT, ELISA and WB were considered as important diagnostic tools. 
 
1.13.3.1. Complement fixation test (CFT): 
Complement fixing antibodies appear in 95% of cases from the third week 
of infection and disappear within 6 months of cure (Manson & Bahar, 1987). The 
antigen is prepared from L. donovani promastigotes (Manson & Bahar, 1987). A 
titer of 1/10 is suggestive and a titer of 1/40 is diagnostic (Manson & Bahar, 1987). 
The problem with CFT is that it can give false positive results with tuberculosis, 
leprosy and less commonly with malaria. Persistence of a low titer is a clue to 
relapse. 
1.13.3.2. Indirect haemagglutination test (IHT): 
The haemagglutination test follows the same course as CFT (Manson & 
Bahar, 1987) .The antigen is in a soluble form prepared from promastigotes 
adsorbed into tanned sheep erythrocytes and latex particles. It is a sensitive and 
specific test (Manson & Bahr, 1987). A titer of 1/200 and over is diagnostic (Bray, 
1976). 
1.13.3.3. Indirect fluorescent antibody test (IFAT): 
  This is a sensitive and specific test in diagnosing VL (Manson & Bahr, 
1987). However, other studies reported a sensitivity of 75% and a specificity of 
93% as compared to ELISA (Ashford et al., 1993).       
          The antigen is prepared either from promastigotes fixed with acetone or I, 
form a mastigotes isolated from an infected animal. It is particularly important in 
screening and detecting early cases of kala-azar (Manson & Bahr, 1987) as it 
becomes positive early in the disease and disappears within 6 months of cure. 
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Persistence of antibodies for more than 2 years is indicative of relapse and is also a 
measure of the response to treatment (Manson & Bahar, 1987). 
          The disadvantage of the test is its cross-reaction with T.cruzi (Shaw & 
Volter, 1964; Bray & lanson, 1965; Manson & Bahar, 1987) malaria, 
schistosomiasis and leprosy as well as typhoid and larva migrans infestation 
(Manson & Bahr, 1987). Another disadvantage is that the test needs a fluorescent 
microscope and it is not suitable for large scale epidemiological studies. 
1.13.3.4. Enzyme linked immunosorbent assay (ELISA): 
The use of enzyme linked assay with an antigen or an antibody was first 
described by (Engvall and Perlman 1971, 1972).They assessed the antibodies 
present in rabbit sera by using disposable polystyrene tubes and alkaline phosphate 
as a conjugate and when compared with RIA they showed that ELISA was 
sensitive. Since that time ELISA has been widely adopted in the serodiagnosis of 
parasitic diseases like malaria, trypanosomiasis, giardiasis, schistosomiasis, ect... 
(Voler et al, 1980). 
 The principle of the test is that the antigen is adsorbed to a solid phase 
(polystyrene surface) by physical adsorption to which is added the serum and the 
enzyme labeled anti-immunoglobulin that retains both the immunological and the 
enzyme activity. The intensity of the colour produced when the substrate specific 
for the enzyme is broken is proportional to the amount of the specific antibody 
present in the serum (Voler et al., 1980). The test was shown to have a sensitivity 
of 98.4% and specificity of 100%. 
1.13.3.5. Immunoblotting (Western Blot WB): 
         The performance of Leishmania soluble antigens for VL diagnosis was 
improved through electrophoretic separation of individual reactive epitopes as in 
immunoblotting techniques (Jaffe & Zaiis, 1988). Incorporation of purified 
polypeptides of L.infantum in such a technique provided in addition to the high 
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potential for VL diagnosis also the means to study the evolution of antibody 
responses throughout the course of infection. The optimal sensitivity of 
immunoblotting techniques and in particular the Western Blot (WB) was further 
demonstrated in patients with VL/HIV co-infection. Nevertheless Hoerauf et al 
(1992) demonstrated the capability of the immunoblot technique to differentiate 
kala-azar from lymphoproliferative and autoimmune diseases that could not be 
differentiated by ELISA and IFAT. However the technical and financial factors 
involved constituted significant obstacles for the applicability of immunoblotting 
techniques at the central laboratories of various VL endemic areas. In sudan 
(Bucheton et al 2003) analysed Leishmania-specific antibodies by enzyme-linked 
immunosorbent assay and immunoblotting. Immunoblot analysis detected 
antibodies to Leishmania in 80% of the healthy subjects and half of them 
harboured high immunoglobulin (Ig) G antibody levels, similar to those of VL 
patients. These antibodies belonged to the IgG1 and IgG3 subclasses but neither 
their respective levels nor the immunoblot recognition patterns were predictive of 
VL. 
1.13.3.6. Direct agglutination test (DAT): 
The direct agglutination test is a simple and feasible technique that has high 
sensitivity and specificity (Harith et al., 1986, 1988, Hommel, et al., 1997; 
Meredith et al., 1995). Because of these advantages it is one of the most widely 
used immunological tests that have been applied by several investigators in 
diagnosis and epidemiological studies. In this test the antigen preparation consists 
of the whole organism (promastigotes) and the serological response (mainly IgG) 
to surface borne antigens is measured. Nicloe and Manceaux in 1909 were the first' 
to describe agglutination in the serum of patient with Leishmania while the first 
diagnostic application in the serum of patient with Leishmania of the agglutination 
test was performed by Row in 1931 (cited by Hommel et al., 1997). Increased 
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specificity of the test was obtained by trypsinization of antigen. The DAT was 
modified by (Harith et al 1986) who described formalin-fixed trypsinized 
promastigotes stained with coomassie brillant blue and used as an antigen in a 
reusable V-well microtitre plates. The sensitivity and specificity of the DAT were 
further improved by testing the serum samples in serum diluent containing gelatin 
instead of fetal calf serum and 0.1 ml 2-mercaptoethanol (Harith et al., 1988). 
Cleaving agents other than trypsin e.g pronase lipase pancreatin or 2-
mercaptoethanol were evaluated for further improvement of the test (Harith et al., 
1995).  
The test was recommended to be used widely in sero-epidemiological 
surveys.(EL Harith et al 1996) showed that the DAT was valuable in 
differentiating PKDL from other skin conditions like leprosy. 
 According to (Hommel et al 1997) the possible cross-reactivity with other 
pathogens including T brncei, T. cruzi and Mycobacteria Tuberculosis are the 
critical problem in the DAT. Andrade et al (1987) showed that L. donvani DAT 
antigen could be used for the diagnosis of VL caused by L. chagasi in Brazil. 
(Harith et al 1988) found cross- reactivity with serum samples from patients with 
African trypansomaisis and toxoplasmosis. 
These cross reactions were eliminated by the addition of 2- mercapto 
ethanol to the serum diluents. The decline of anti-leishmanial antibodies level in 
VL patients following treatment has been a subject for intensive research in the 
course of DAT evaluation. (Hailu 1990) found that significant level of anti 
leishmanial antibodies may be present up to 7 years after treatment. Like as most 
serological tests, DAT may not differentiate between active disease, sub clinical 
and pervious infections and this is a major draw back to the test (Hommel et al., 
1997; Zijistra et al., 1991). Another major draw back to DAT is the limited 
stability of the aqueous antigen (Harith et al., 1988). Of due to that, a DAT based 
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on stable - freeze -dried antigen has been developed. High sensitivity (92%) and 
specificity (99.7%) of the freeze dried antigen were shown to be identical to that of 
aqueous antigen (Oskam et al., 1999). The freeze -dried antigen can be stored at 
ambient temperature. Due to these factors the test became one of the best available 
diagnostic tools for use in the field. 
1.13.3.7. Latex agglutination test (LAT): 
          In search for a quick simple serodiagnostic test, many researchers  sensitized 
the latex particle with Leishmania antigens. De Korte et al 1990) performed LAT 
sensitized by L. infantnm soluble antigen for the detection of anti-Z,. infantum 
antibodies in canine VL reservoir in southern France but they obtained a lower 
sensitivity for LAT in comparison to DAT. (Moody & El Safi 1996) performed the 
LAT (using L. donovani soluble antigen) in sera from Sudanese VL confirmed 
cases (n= 60), VL unconfirmed cases (n=48) but with positive DAT result and sera 
from healthy non endemic controls (n=75) they reported a sensitivity of 88% and 
specificity of 100%. They concluded that the LAT is a simple and practical 
serological technique for the diagnosis of VL particularly at dispensary level but 
they recommended further evaluation of LAT using fresh sera. In study done for 
evaluation and development of  latex agglutination test ; using plain latex, 
carboxylated latex and magnetic beads. They found that the sensitivity was 95%  
and specificity of 90%( Ahmed abdAllah thesis) 
1.13.3.8. Latex agglutination test (Katex) for detection of urinary antigen: 
          Katex is a new latex agglutination test for the detection of leishmanial 
antigen (Ag) in the urine of patients with VL (Attar et al., 2001; Hommel et al., 
2001;). The detected Ag which is a heat-stable, precipitates with acetone and 
ethanol but not Tri acidic acid, is sensitive to periodate and acid hydrolysis but not 
to Pronase E, Lipase,or neuraminidase. The Ag is a low molecular weight glycol 
conjugate that can be extracted by phenol water, the molecular weight of urinary 
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Ag is 5-20 KDA was detected in the urine of patients from Nepal, Sudan ,Brazil, 
Yemen and Spain and experimentally infected animals (Sarkari et al., 2002) . No 
low molecular weight antigen was detected in the urine of patients with malaria, 
schistosomiasis, or diseases such as typhoid and brucellosis (Sakari et al., 
2002).The antigen is detectable in both the promastigote and amastigote stages of 
the parasite. Monoclonal antibodies (mAbs) against Leishmania glycoconjugates 
strongly react with this molecule, so that the detected antigen is highly specific and 
diagnostic for VL.  
           The test is based on the adsorption of anti-leishmanial antibody to latex 
particles; this reagent agglutinates within two minutes when mixed with urine from 
an infected host. To obtain adequate specificity urine can be boiled before 
performing the test. As antigen detection tests the Katex would in principle provide 
better means for diagnosis since antigen level are expected to broadly correlate 
with the parasite load. Antigen detection systems are also ideal alternative to the 
antibody detection systems in immuno compromised patients. Katex is simple test 
and easy to perform. It does not require specialized equipment and easy to 
interpret. The test is 100% specific and 80% sensitive with parasitologically 
confirmed cases from Brazil, Sudan, Yemen and Nepal (Attar et al., 2001).  
1.13.3.9. rk39 strip test: 
A test based on a 39-amino-acid-repeat recombinant leishmanial antigen from 
Leishmania chagasi (rK39) has been introduced into an enzyme-linked 
immunosorbent assay (ELISA) and, later, an immunochromatographic strip tes for 
the diagnosis of VL (Zijlstra,  et al. 1998). The rK39 strip test is reported to be 
simple, sensitive, specific, non-invasive and economical test (Singh et al., 2009)  
 
The test seems an ideal qualitative test for the diagnosis of kala-azar. But for 
sero-epidemiological studies the test may be used with other parameters. 
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Alternatively a quantitative ELISA using rK39 antigen may be used. (singh et 
al.,2009)  
1.13.4. DNA based detection methods: 
           In recent years several molecular biological techniques have been developed 
for the sensitive detection and identification of pathogens (Denissereno et al., 
2003) .The main approaches to nucleic acid based detection are: (1) by 
hybridization using DNA probes and (2) amplification techniques including 
NASBA, RT.PCR for the detection of RNA and the PCR for detection of DNA. In 
one study, none of patients treated for VL who tested negative by PCR with lymph 
node tissue relapsed or developed PKDL, while more than half of patients who 
tested positive by PCR with lymph node tissue either relapsed or developed PKDL 
after apparent cure of disease following supervised treatment (Osman et al., 1995).  
 A group of Sudanese researchers who used PCR for detection of reservoir 
hosts headed by (EL Hassan et al 1993) detected Leishmania DNA in Arvicanthns 
niloticiis. 
The availability of DNA based diagnostic methods has allowed more 
sensitive, rapid detection and characterization of microorganisms .The association 
of hybridization with the PCR has solved relatively limited sensitivity of 
hybridization and has been used with efficacy for the diagnosis of genetic and 
infectious_ diseases including protozoan parasites (Ashford et al., 1995).  
(Scharfer et al 1995) examined the sensitivity of PCR for detection of 
parasite DNA before and after diagnosis and treatment. They found that PCR 
detects sub clinical VL cases; i.e. have detectable circulating DNA in their blood 
.They showed that L. donovani DNA can be detected in the blood despite negative 
serological tests, and absence splenomegaly .In addition, they found that parasite 
DNA can be found in blood dried on filter paper long before a parasitological 
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diagnosis of VL is made of helps to provide them to center involved in clinical 
trials and parasite characterization (WHO, 1996).  
1.14. Treatment: 
            Pentavalent antimonial drugs have been used in the treatment of VL since 
1916 (Manson & Bahr, 1987). They are the first line of VL treatment. They are 
available in form of sodium antimony gluconate (Pentostam) and meglumine 
antimonate (Glucantime) at the rate of 85mg/ml pentostam available in vials 
(50ml) which contain 600mg. It can be given intramuscularly or intravenously at a 
daily dose of 20mg/kg body weight for a bout 30 days. Antimony compounds act 
against Leishmania parasites by inhibiting purine nuclear and macro cellular 
synthesis (Bracyson, 1987). Renal function has to be assessed before and during 
drug treatment because 60-80% of the drug'is renally excreted. It is also 
cardiotoxic and can produce fatal arrythmias in high dosage especially during the 
second week after commencing treatment (Chowdhury et al., 1998). Most of the 
patients respond well to antimonial compounds .Other drugs used include 
pentamidine but it has side-effects. Amphotericin B kills the parasite intra and 
extracellularlly but is nephrotoxic .The new formulation of Amphotericin with 
lipid (Ambisome) fortunately devoid of the toxicity of Amphotericin B (Hoiumeur 
et al., 1998) and can be used for VL patients who are not responding to the 
treatment of ka azar patients and they enhance intracellular killing of the 
parasites. A single infusion of liposomal amphotericin B was not inferior to and 
was less expensive than conventional therapy with amphotericin B 
deoxycholate.(Sundar et al.,2010)  INF.λ has been used for the treatment of Kala -
azar patients and it also enhanced intracellular killing of Leishmania and when 
used in combination with antimonial compounds in refractory VL cases gave 
satisfactory results (Murray et al., 1988). All the current drugs for kala-azar have 
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draw backs .They are administered by injection or infusion and require the patients 
to be hospitalized. Miltefosine is expected to be the first oral treatment of kala- 
azar in Bihar-India (TDR News, 1999).  
2. HIV /AIDS:  
Human immunodeficiency virus (HIV) types derived from primates 
(Lentiviruses) are the etiologic agents of AIDS (Geo & Butel, 1998).Scientists 
identified a type of chimpanzee in West Africa as the source of HIV infection in 
humans. The virus most likely jumped to humans when humans hunted these 
chimpanzees for meat and came into contact with their infected blood. Over 
several years, the virus slowly spread across Africa and later into other parts of the 
world (CDC.2009) 
The illness was described for the first time in 1981 by Luc Montagnier of 
France and Robert Gallo of the United States. AIDS etiologic agent HIV-1 was 
isolated by the end of 1983. Since then AIDS has become a worldwide epidemic 
expanding in scope and magnitude. 
About 54,862,417 persons were estimated in November 2003 to be 
infected worldwide, 30% of them were in South Africa (Kahn et al., 1998). Once 
they contract the disease, individuals remain infected for life if left untreated. The 
vast majority of HIV infected individuals develop fatal opportunistic infections 
such as tuberculosis as a result of HIV-induced deficiencies in the immune system. 
AIDS is one of the most important public health problems world-wide at the start 
of the 21st century (How et al., 1998). 
2.1. Virus morphology & structure:  
The virion of the HIV is spherical 80-100µm in diameter, of cylinderic 
core. The genome is single strand RNA, linear, positive sense 9-10 kilobases in 
length, diploid and contains up to six additional replication genes (Geo & Butel, 
2001). The mature virion has three morphologic components:  
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       -An outer envelope made up of lipid bilayer membrane containing virus 
specific glycoprotein spikes.  
       -An internal protein capsid, within the capsid, a nucleocapsid and two 
virally encoded enzymes (Reverse transcriptase and integrase).   
In addition, unique cellular tRNAs are associated with each segment of the 
viral genome.  
The Lentivirinae subfamily to which HIV belongs is characterized by a 
distinctive nucleocapsid core viewed in electron microscope as a bar or truncated, 
cone-shaped nucleocapsid.  
HIV has three major genes coding for structural proteins. These are gag, 
pol and env. The gag-derived proteins make up the viral capsid p 24, i.e. a 24 
kilodaltan protein, the nucleocapsid protein (p17) and a matrix protein.  
The pol gene a code for the virus enzymatically active proteins most 
important of which is reverse transcriptase, which performs the unique reverse 
transcription of the viral RNA into double stranded DNA.  
Also pol encodes a specific viral protease. This enzyme cleaves gag and 
gag-pol derived protein into functional pieces. The third structural gene, env, 
stands for "envelope". The proteins derived from env are a surface (gp 120) and a 
transmembrane proteinTM (gp 41) (Geo & Butel, 2001). 
The TM (gp41) env product contains both a transmembrane domain that 
anchors the glycoprotein in the viral envelope and a fusion domain that facilitates 
viral penetration into target cells. The divergence in the envelope of HIV 
complicates efforts to develop an-effective vaccine for AIDS (Volk et al., 1996). 
2.2. Target cells and mechanism of infection: 
            HIV primarily infects cells with CD4 cell surface receptor molecules, using 
them to gain entry. HIV use CD4 molecule as receptor, which is expressed on 
macrophages and T lymphocyte. HIV may use galactosyl cermide as receptor in 
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place of CD4 in neural cells. Second important receptor is necessary for HIV-1 to 
gain entry to cells is chemokine receptors, chemokines are soluble factor with 
chemo- attractant and cytokine properties. CCR5, the receptor for chemokines 
RANTES, MIP.1α, and MIP.1B, is the receptor for macrophage-tropic strains of 
HIV-1. In contrast, CXCR4, the receptor for chemokine SDF-1, is the necessary co 
receptor for lymphocyte-tropic strains of HIV-1 (Buseyne et al., 1998).  The 
presumed mechanism is that HIV needs to bind to both a T cell CD4 receptor and 
to a co-receptor (Buseyne et al., 1998). The viruses first bind to CD4 and then to 
the second receptor, this interaction causes conformational change in the viral 
envelope activating the gp41 fusion peptide and triggering membrane fusion. There 
is evidence that individuals who possess homozygous deletion in CCR5 may be 
protected from infection by HIV-1. Genetic variation in the chemokine co-receptor 
molecule results in less effective HIV binding and thus slows HIV replication.  
              Studies show that a homozygous deletion (delta-32) in the gene coding for 
the chemokine receptor CCR5 significantly lowers, but does not eliminate 
completely, the risk of HIV infection. (Liu et al., 1996; Huang et al., 1996; Samson 
et al., 1996; Dean et al., 1996; Theodorou et al., 1997; Biti et al., 1997). A second 
genetic variant (CCR2-64I) in the gene coding for the CCR2 receptor is not 
protective against HIV infection, but is associated with slower progression to 
AIDS by 2 to 3 years in heterozygous or homozygous individuals. It occurs in 
roughly 2% of African Americans, Caucasians, Asians, and Hispanics (Smith et 
al., 1997; Kostrikis et al., 1998). A third genetic variant (SDF1-3'A) affects the 
regulatory region of a gene coding for the chemokine SDF-1, which is the ligand 
(the normal binding molecule) for chemokine receptor CXCR4 (Winkler et al., 
1998). 
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2.3. Replication Cycle:  
The replication cycle of HIV-1 include the following: 
A. Virus entry: 
            The first step is adherence of HIV by gp 120 to host cells, (Capon & Ward, 
1991) that contain in their surface, the CD4 membrane antigen as receptor, which is 
found on T.lymphocyte (Bhat et al., 1993). These cells have specific chemokine 
receptors, (Alkhatib et al., 1996) known as co-receptor, (Deng et al., 1996) such as 
CCR5 or HIV-1R5, which is present in the early stages of the disease. (Alkhatib et 
al., 1996; Deng et al., 1996; Dragic et al., 1996), and CXCR4 or HIV-1X4 which 
is seen during late stages of the disease (Chose et al., 1996; Doranze et al., 1996 ). 
The second steps after attachment to host cells surface is penetration of HIV-
1virion into host cells. The gp41 is responsible for this (Stein et al., 1987; McClure 
et al., 1988, 1990).  
B. Replication: (Reverse transcription &Integration) 
            After internalization, the HIV virion is uncoated and its RNA is copied and 
generates a single stranded DNA copy (Katz & Shalka, 1990). This reaction is 
mediated by the Reverse Transcriptase, an RNA-and DNA-dependent DNA 
polymerase and RNase H, which degrades the RNA component of RNA-DNA 
hybrid molecules (Katz & Shalka., 1990). Then the second DNA strain is formed, 
also mediated by Reverse Transcriptase, which produce large amount of DNA 
(Shih et al., 1988). The recently formed double stranded DNA penetrates the 
nucleus as part of the pre integration complex reaction. The nuclear viral 
complexes serve as the machines that integrate viral DNA into host cell 
chromosomal DNA to form provirus. This step is dependent on the activity of the 
viral Integrate protein (Pryciak & Varmus, 1992). 
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C. Proviral DNA: 
             Following the integration of the recently synthesized viral DNA into the 
host DNA, this proviral DNA start to encode viral protein formation. Initially, viral 
mRNA is transcribed by proviral DNA and this mRNA mediated by host cell RNA 
polymerase, initiates synthesis of large poly proteins encodes the regulatory and 
structural viral proteins (Jacks et al., 1988; Parkin et al., 1992; Chamorro et al., 
1992). 
D. Budding:  
             After formation of HIV structure, the virion assembles into the cytoplasm. 
HIV is released from the cell by budding. It acquires it’s lipid membranes from the 
host cell membranes after this budding, the protease enzyme cleaves the virion 
poly protein leading to maturation of the infections viral particle. In the productive 
growth cycle the host cell is destroyed (Earl et al., 1991). 
2.4. Pathogenesis: 
The typical course of untreated HIV infection spans about a decade. The 
stages include the primary infection, dissemination of virus to lymphoid organs, 
clinical latency, elevated HIV expression, clinical disease and death (Geo, 1998).  
The duration between primary infection and progression to clinical disease 
averages about 10 years. Through untreated cases death usually occurs within 2 
years after the onset of clinical symptoms.  
Following primary infection, there is a 4-11 days period between mucosal 
infection and initial viraemia; viraemia is detectable for about 8-12 weeks, virus is 
widely disseminated trough out the body during this time and the lymphoid organs 
become seeded.  
An acute mononucleosis-like syndrome develops in many patients (50-
75%) 3-6 weeks after primary infection (Geo, 1998).  There is significant drop in 
numbers of circulating CD4 T cell at this early time. An immune response to HIV 
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occurs 1 week to 3 months after infection, plasma vireamia drops and levels of 
CD4 cells rebound. However the immune response is unable to clear the infection 
completely and HIV infected cells persist in the lymph nodes.  
This period of clinical latency may last for as long as 10 years. During this 
time there is a high level of ongoing viral replication. It's estimated that 10 billion 
HIV particles are produced and destroyed each day. The half life of the virus in 
plasma is about 6 hours and the virus life cycle (from the time of infection of a cell 
to the production of new progeny that infect the next cell) averages 2 – 6 days.  
CD4 T lymphocytes are the major targets responsible for virus production; 
appear to have similar turnover rates (Geo, 1998).  Once infected, the half life of 
CD4 T lymphocyte is about 1 – 6 days. Because of this viral proliferation and the 
inherent error rate of the HIV reverse transcriptase, it is estimated that every 
nucleotide of the HIV genome probably mutates on a daily bases. 
HIV found in patients with late stage disease is usually much more 
virulent and cytopathic than the strains of virus found in early infection(Geo, 
1998). Often a shift from monocyte or macrophage tropic (M-tropic) strains 
accompanies progression to AIDS.  
The cardinal feature of HIV infection is depletion of T helper, inducer 
lymphocytes, as a result of the tropism of HIV for this population of lymphocytes, 
which express the CD4 phenotypic marker on their surface (Geo, 1998).  The CD4 
molecule is the major receptor for HIV; it has a high affinity for the viral envelope. 
The HIV co-receptor on lymphocytes is the CXCR4 chemokine receptor. Early in 
infection primary HIV isolates are M-tropic. However, all strains of HIV infect 
primary CD4 T cells (but not immortalized T cell lines in vitro). As the infection 
progresses the dominant M-tropic viruses are replaced by T-tropic viruses. 
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Laboratory adaptation of these primary isolates in immortalized T cell lines, results 
in loss of ability to infect monocytes and macrophages.  
The consequences of CD4 T cell dysfunction caused by HIV infection are 
devastating because the CD4 T-lymphocyte plays a critical role in the human 
immune response. It is responsible directly or indirectly for induction of a wide 
array of lymphoid and non-lymphoid cell functions. These effects include 
activation of macrophages, induction of functions of cytotoxic T cells, Natural 
killer cells, B cells and secretion of variety of soluble factors that induce growth 
and differentiation of lymphoid cells and affect haematopoietic cells (Geo, 1998).   
Monocytes and macrophages play a major role in the dissemination and 
pathogenesis of HIV infection. Certain subsets of monocytes express the CD4 
surface antigen and therefore bind to the envelope of HIV. The HIV co-receptor on 
monocyte and macrophage is the CCR5 chemokine receptor.  
Infected pulmonary alveolar macrophages may play a role in the 
interstitial pnemuonitis seen in certain patients with AIDS.  
Macrophage tropic strains of HIV predominate early after infection, and 
these strains are responsible for initial infections even when the transmitting source 
contains both M-tropic and T-tropic viruses.  
It's believed that monocytes and macrophages serve as major reservoirs 
for HIV in the body. Unlike the CD4 T cell, the monocyte is relatively refractory to 
the cytopathic effects of HIV, so that the virus can not only survive in this cell but 
can be transported to various organs in the body such as lungs and brain (Volk et 
al., 1996).  
Lymphoid organs play a central role in HIV infection. Lymphocytes in the 
peripheral blood represent only about 2% of the total lymphocyte pool, the 
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remainder being located chiefly in lymphoid organs where specific immune 
responses are generated.  
Throughout the course of untreated infection, even during the stage of 
clinical latency, HIV is actively replicating in lymphoid tissues where it is ideal for 
the establishment and spread of HIV infection. Cytokines are released activating a 
large pool of CD4 T cells that are highly susceptible to HIV infection. As the late 
stage of HIV disease progresses, the architecture of the lymphnodes becomes 
disrupted.  
Neureologic abnormalities are common in AIDS and occur to varying 
degrees in 40-90% of patients. These include HIV encephalopathy, peripheral 
neuropathies and most serious AIDS dementia complex. Both direct and indirect 
pathogenic mechanisms might explain the neuropsychiatric manifestations of HIV.   
Virus may enter the brain through infected monocyte and release 
cytokines that are toxic to neurons as well as chemotactic factors that lead to 
infiltration of the brain with inflammatory cells. HIV has been found in a limited 
number of neurons, oligodendrocytes and astrocytes.  
HIV infected persons develop both humoral and cell mediated response 
against HIV related antigens. Antibodies to a number of viral antigens develop 
soon after infection, but the response pattern against specific viral antigens changes 
over time as patient progress to AIDS.  
Antibodies to envelope glycoproteins (gp 41, gp 120, gp 160) are 
maintained but those directed against the core protein (p24) decline. The decline of 
Anti p24 may herald the beginning of clinical signs and other immunologic 
markers of progression.  
Most infected individuals make neutralizing antibodies against HIV. The 
neutralizing antibodies can be measured in vitro by inhibiting HIV infection of 
susceptible lymphocyte cell lines.  
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 Cytotoxic T- lymphocytes recognize env, pol and gag genes products, 
this reactivity is mediated by major histocompatiability complex restricted to CD3 
and CD8 lymphocytes. The env specific reactivity occurs in nearly all infected 
people and decreases with progression of disease. Natural killer cell activity has 
also been detected against HIV-1 gp 120. It's not known which of these host 
responses is important in providing protection against HIV infection. A problem 
confronting AIDS vaccine research is that the correlates of the protective immunity 
are not known, including the relative importance of humoural and cell-mediated 
immune response (Geo et al., 1998). 
 
2.5. Transmission:  
HIV is transmitted during sexual contact (including genital-oral sex), 
through parenteral exposure to a contaminated blood or blood products and from 
mother to child acquiring infection through breast-feeding, during birth and during 
prenatal period is probable (Volk et al., 1996). The presence of other sexually 
transmitted diseases such as syphilis, gonorrhea, or chancroid increases the risk of 
sexual HIV transmission as much as a hundred folds, because the inflammation 
and sores facilitate transferring of HIV across mucosal barriers. Since the first 
description of AIDS, promiscuous homosexual activity has been recognized as a 
major risk factor for acquisition of the disease.  
Furthermore health care workers usually get infection by HIV following a 
needle stick with contaminated blood.  
There has been considerable concern that in rare circumstances other 
types of transmission may occur such as through "casual" contact with HIV 
infected persons or insect vectors, but there is no evidence of virus transmission 
under these casual conditions (Volk et al., 1996).  
 
36 
 
2.6. Peripheral Blood in AIDS: 
Cytopenias are commonly seen in association with HIV infection, anemia, 
thrombocytopenia, neutropenia, lymphocytopenia, monocytopenia, or 
combinations of any or all of these can occur in over 90% of patients with AIDS. 
The microenvironment of the marrow may also be altered by HIV infection of 
stromal cells including fibroblasts, endothelial cells, reticular cells, macrophages, 
osteoclasts, and steatocytes, resulting in dysregulation of hematopoietic cell growth 
with reduced hematopoiesis.( Moses et al., 1998) Anemia is present in over half of 
patients early in the course of AIDS and in nearly all AIDS patients late in the 
course. The anemia is often normochromic and normocytic, typical of anemia of 
chronic disease, and iron stores are increased by measurement of serum ferritin. 
Though CD34 stem cells poorly express CD4 receptors and, hence, are relatively 
resistant to HIV infection, mononuclear cells are infected and produce cytokines 
such as TGF, TNF, and IL-1 that suppress hematopoiesis. Cytopenias can be 
potentiated by drug therapy including zidovudine (ZDV), ganciclovir, 
amphotericin B, or trimethoprim-sulfamethoxazole and may require dose reduction 
or cessation of therapy. Though a positive direct antiglobulin test may be present in 
up to 43% of HIV-infected persons, hemolytic anemia is uncommon.( Volberding  
et al., 2003) anemias in AIDS occasionally may results from use of drugs that act 
as folate antagonists (trimethoprim-sulfamethoxazole). 
Thrombocytopenia is commonly seen in about a third of AIDS cases, is 
rarely severe, and may result from peripheral consumption (splenomegaly, immune 
complexes) or from decreased marrow platelet production. Thrombocytopenia may 
also appear in some HIV-infected persons prior to development of clinical AIDS, 
and most cases are due to platelet consumption.    
Lymphopenia is present in about a third of AIDS cases due to the decrease 
in T4 lymphocytes.  
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Neutrophilia may indicate bacterial sepsis. Bone marrow failure leading to 
death in patients with AIDS is very uncommon.( Jacobson et al .,1997; Moses et 
al.,1998;Volberding et al., 2003; Meynard et al.,1997).   
Neutropenia that accompanies HIV infection can increase the risk for 
infection or worse the course of infection. Neutropenia can be common in patients 
with AIDS and is a risk factor for both bacterial and fungal infections. The most 
common cause for neutropenia is drug therapy.   Neutropenia can result from 
involvement of bone marrow by opportunistic infections, from pharmacologic 
therapies such as trimethoprim-sulfamethoxazole, and from direct effects of HIV 
through accelerated apoptosis. Both chemotaxis and phagocytic functions of 
neutrophils also appear to be impaired.   
Thrombosis is more likely to occur when the CD4 count is less than 
200/µl. ( Volberding  et al., 2003; Copur et al., 2002). The antiphospholipid 
syndrome has been reported in association with HIV infection ( Leder et al., 2001). 
2.7. Acquired immunodeficiency syndrome (AIDS): 
AIDS is a group of clinical syndrome caused by HIV, characterized by 
profound immune suppression with diverse clinical features, including 
opportunistic infection, malignancies and central nervous system. (Osmond et al., 
1991) Acute renal failure remains common among hospitalized patients with HIV 
and is associated with chronic kidney disease, liver disease, and increased 
mortality (Christina, et al.2006).  
Classification  
 
Two major classification systems currently are in use: the U.S. Centers for 
Disease Control and Prevention (CDC) classification system  (CDC, 1992) and the 
World Health Organization (WHO) Clinical Staging and Disease Classification 
System. (WHO. 2007)  
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             The CDC classification of HIV disease was first put forth as a 
categorization of HIV related symptoms into four groups and was explicitly for 
"public health purposes" and not "intended as a staging system,"  although it was 
frequently treated as if it were a staging system in the AIDS literature(CDC, 1986). 
Staging is disease classification that aims primarily to make groupings that have 
different prognosis and can be used in guiding treatment decisions. Stages attempt 
to classify disease in a progressive sequence from least to most severe, each higher 
stage having a poorer prognosis or different medical management than the 
preceding stage. The current CDC classification system from the revision in 1993 
combines three categories of the CD4 count with three symptom categories and are 
closer to a staging system. This description of its intended use is close to the use of 
a staging system (CDC, 1993). 
CD4T-lymphocyte categories:  
Category 1: > 500 cells/µl (or CD4% > 28%)  
Category 2: 200-499 cells/ µl (or CD4% 14% - 28%)  
Category 3: < 200 cells/ µl (or CD4% < 14%) 
Categories of clinical conditions:  
Category A 
              A symptomatic HIV infection, persistent generalized lymphadenopathy 
acute (primary) HIV infection with accompanying illness or history of acute HIV 
infection in an adolescent (>13 years) with documented HIV infections. Conditions 
listed in categories B and C have not occurred. 
Category B 
            Consists of symptomatic conditions in an HIV infected adolescent or adult 
that are not included among conditions listed in clinical Category C and that meet 
at least one of the following criteria:  
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A\ The conditions are attributed to HIV infection or are indicative of a defect in 
cell mediated immunity.  
B\ the conditions are considered by physicians to have a clinical course or to 
require management that is complicated by HIV infection. 
Category C  
            Includes the clinical conditions listed in the 1993 AIDS surveillance case 
definition. For classification purposes, once a Category C condition has occurred, 
the person will remain in Category C (Dennis, 1998).    
The WHO system classifies HIV disease on the basis of clinical manifestations that 
can be recognized and treated by clinicians in diverse settings, including resource-
constrained settings, and by clinicians with varying levels of HIV expertise and 
training. (WHO. 2007)  
S: When a patient presents with a diagnosis of HIV infection, review the patient's 
history to elicit and document any HIV-related illnesses or symptoms   
O: Perform a complete physical examination and appropriate laboratory studies  
A:Confirm HIV infection and perform staging.  
P:Evaluate symptoms, history, physical examination results, and laboratory results, 
and make a staging classification according to the CDC or WHO criteria(WHO. 
2007) . 
2.8. Clinical manifestation :  
           The clinical manifestations of HIV disease include five stages, primary 
infection, and early, middle-, advanced-, and late-stage HIV disease (Osmond 
Dennis H 1998). These stages of HIV infection goes on the primary infection, 
dissemination of virus to lymphoid organ, clinical latency, elevated HIV 
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expression, clinical disease, and death. There is much individual variation in the 
clinical manifestations of individual patients in the same disease stage and in the 
rate of progression through the stages.  
           The duration between primary infection and progression to clinical disease 
in untreated individuals averages about 10 years (Bacchetti & Moss, 1989). The 
estimate varies with the age at which infection occurs and is significantly shorter in 
infants and in older adults and varies even between infection at age 20 and 
infection at age 40. Death usually occurs within 2 years after the onset of clinical 
symptoms (Rosenberge et al., 1994). 
2.8.1. Primary infection:  
          Often symptoms less, but when present appear to result from immunopathic, 
lymphocytopathic, and neuropathic. Sometimes symptoms present with an 
infection mononucleosis-like illness, during 2 weeks to 3 months after exposure. 
Reported manifestations include fevers, fatigue, malaise, arthralgias, myalgias, 
lymphadenopathy, splenomegaly, anorexia, nausea and vomiting, diarrhea, 
pharyngitis, headache and retroorbital pain, meningitis and encephalitis, 
neuropathy, myelopathy, maculopapular rash, and mucocutaneous ulceration. 
Lymphadenopathy onset typically occurs in the second week of the syndrome and 
may be generalized or preferentially affect the occipital, axillary, and cervical 
groups, fevers, rash, sore throat, night sweats, malaise, Lymphadenopathy, 
diarrhea, and relative and absolute lymphocytosis in the peripheral blood. There 
may be mouth and genital ulcers, a profound transient decrease in CD4 
lymphocyte. (Schacker et al., 1998; Keet et al., 1993; Schechter et al., 1990; 
Pantaleo et al., 1997; Niu et al., 1993; Henrard et al., 1997). 
2.8.2. Early and Middle stage:  
           The early and middle stage of HIV disease followed the primary infection 
after at least three-month. In which the level of detectable virus in peripheral blood 
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drop dramatically and antibodies rise (Phillips, 1996). This period of clinical 
latency may last for as long as 10 years, during which the patients may show, 
depressed count of CD4 lymphocyte (from normal to 200 to 300cells\µl). Through 
the subsequent early and middle stages of HIV disease, the level of virus detectable 
in the peripheral blood often remains low (Pantaleo et al., 1998). 
           Clinical manifestations are usually minimal or no symptoms, other 
individuals, however have subjective systemic symptoms, such as fatigue and a 
few have fevers. Many patients have painless stable lymphadenopathy, which in 
some cases actually regresses as HIV disease advances. Allergy to skin testing 
becomes increasingly probable as the CD4count falls beyond 400 cells/µl, with 
obvious implications for tuberculosis screening ( Pantaleo et al., 1998).  
2.8.3. Advanced HIV disease:  
            Untreated patients with manifestation of advanced HIV diseases typically 
have CD4 counts below 200 cells/ µl, increased plasma HIV RNA levels, and 
clinical manifestation indicative of sever immunocompromise, and in addition 
opportunistic infections commonly occur. In the absence of prophylaxis, 
Pneumocystis Carinii Pneumonia (PCP), is the most common such infection. In-
patients with HIV dementia complex, manifestations typically become profound. 
Systemic symptoms including fever, fatigue, and weight loss are prominent, often 
without identifiable secondary causes. Cryptosporidium diarrhea is a common 
problem with limited treatment options, and the probability that it will resolve or 
remit decrease HIV disease progress. HIV plasma RNA levels typically are high 
(Ioachim, 1990). 
2.8.4. Late-stage HIV disease:  
            As the disease advances further and the CD4 count drops below 50 
cells\mm, additional opportunistic infection as well as central nervous system 
occur commonly, and in homosexual males, existing Kaposi Sarcoma may become 
42 
 
extensive, and cause disfigurement and clinically significant edema. Central 
nervous system toxoplasmosis, Cryptococcal Meningitis, cytomegalovirus (CMV) 
disease, and Mycobacterium Avium Complex (MAC) disease is frequent. Infection 
such as MAC, CMV, Strongyloides Stercoralis, Herpes Zoster or Tuberculosis, 
which normally colonize superficially or are limited to an organ system or a local 
anatomic region, may invade tissue or disseminate widely. Simultaneous clinically 
significant infection by more than one pathogen is common. Secondary symptoms 
become increasingly problematic, including anorexia, nausea, vomiting, diarrhea, 
mal-absorption, muscle wasting, and weakness. 
             Death eventually results from extensive disease of vital organs, most 
commonly the lungs and presumably from effects of circulating toxins, electrolyte 
abnormalities hematopoietic and circulatory failure and autonomic nervous system 
damages (Nguyen et al., 1995). 
Receiving an AIDS diagnosis does not necessarily mean that the diagnosed person 
will die soon; some people have lived for many years after their diagnosis. This is 
even more the case today with the availability of highly active antiretroviral 
therapy (HAART), which has helped extend the lives of thousands of people living 
with HIV and AIDS. In addition, many opportunistic infections can be prevented 
or treated successfully. This has substantially increased the longevity and quality 
of life of people living with HIV/AIDS. (san Fransisco AIDS Foundation.2008).  
2.9. Laboratory diagnosis of HIV:   
Techniques used in the detection of HIV include: screening tests, 
supplemental tests, detection of viral antigen, viral RNA/DNA and direct isolation 
of the virus. (Sangeeta Joshi. 2008). Also other measurements for monitoring 
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disease progression in HIV-1 infected individuals, such as determination of the 
CD4 are helpful. 
2.9.1.ELISA: 
Standard screening tests for HIV include detection of anti-HIV antibodies in 
blood by enzyme immunoassays (EIA/ELISA). These tests use virus antigens 
(proteins) to detect the circulating antibodies. The bound antibodies are detected by 
a colorimetric reaction. These tests become positive 3-12 weeks after infection and 
have more than 99% sensitivity and greater than 95% specificity. The tests can 
detect infection with HIV-1 and HIV-2. However, false positives may occur in 
people with multiple blood transfusions, malignancies, alcoholic hepatitis etc. 
False negatives can occur very early in the infection or in patients who do not 
produce enough detectable antibodies or very late in the infection (Sangeeta Joshi. 
2008). 
2.9.2. Rapid tests :   
These are tests that can yield results in < 30 min. The results are read by naked eye. 
When performed correctly, these are accurate and have wide utility in a number of 
testing situations (Dr Sangeeta Joshi. 2008).Application includes emergency room, 
physician's office, autopsy room, and smaller blood banks.  
Types  
1. Dot blot assays/ tridot  
2. Particle agglutination . Also latex agglutination can be used for initial 
screening; CD4/CD8 ratio correlates infection of HIV (How et a., 1998). 
3. HIV spot and comb tests  
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4. Fluorimetric microparticle technologies  
One class of rapid tests is the 'dot blot' or 'immunoblot'; they produce a well-
circumscribed dot on the solid phase surface if the test is positive. There is a 
color change because of antigen-antibody reaction.  
Disadvantages: 
1. Subjective interpretation  
2. Difficult to read if the laboratorian is color blind.   
Advantages: 
1. Rapid HIV assays have proven particularly useful for testing pregnant women 
in labor who have not received prenatal care.  
2. It is helpful in detecting HIV-2 infection which can not be detected by ELISA. 
(Archana Sharma, YS Marfatia.2008) 
2.9.3. Western Blot (WB):    
It is a more specific assay (Archana Sharma, YS Marfatia.2008); In this antibodies 
against numerous proteins are detected. 
Env (gp160, gp120, and gp41) 
gag (p55, p24, and p17) 
pol (p66, p51, and p31)  
(Archana Sharma, YS Marfatia.2008) 
The western blot method is based on the electrophoresis separation of major 
proteins of an infectious agent in a two- dimensional agarose gel matrix. A 
suspension of the organism against which antibodies are being produced is 
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mechanically or chemically disturbed and the solubilized antigen suspension is 
placed at an end of a polyacrylamide (polymer) gel. Under influence of electrical 
current, the proteins migrate through the gel. Most bacteria or viruses contain 
several major proteins that can be recognized based on their position in the gel 
after electrophoresis. Smaller proteins travel faster and migrate further in the lanes 
of the gel than do the larger proteins. The protein bands are transferred from the 
gel to a nitrocellulose or other type of thin membrane and the membrane is treated 
to immobilize the proteins. The membrane is then cut into many thin strips, each 
carrying the pattern of protein bands. When patient serum is layered over the strip, 
antibodies present can be used to determine whether the patients are infected with 
the agent or not. Antibodies against microbes with numerous cross-reacting 
antibodies, such as T. pallidum, B. burgdorferi, herpes simplex virus types 1 and 2 
and HIV, are identified more specifically using this technology than by methods 
that test for only one general antibody type (Volk et al., 1996). 
2.9.4. Qualitative PCR: 
PCR is a method that amplifies viral nucleic acid to allow for its detection in 
patient specimens. It is a particularly specific and sensitive test which can pick up 
very small numbers of viral particles (M Fearon.2005). PCR is very useful in the 
diagnosis of HIV infection in babies born to infected mothers. Babies will carry 
maternal antibody up to approximately 15 months of age and, therefore, the 
antibody test is not a reliable indicator of infection in these children. 
Because of the very specific nature of the primers used in the HIV-1 DNA PCR 
assay, caution should be used in assessing a negative result in an infant if the 
mother is likely to have HIV-2 or a non-B HIV infection. It may be prudent to 
ensure that the HIV DNA PCR assay is effective in detecting the mother's HIV 
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infection if there is any likelihood that the case is not an HIV subtype B infection. 
In North America, this would be a very uncommon finding. 
PCR may also be useful in resolving indeterminate Western blot results and testing 
immunocompromised individuals who may not mount an antibody response. 
2.9.5.Quantitative RNA PCR and genotyping: 
Quantitative RNA PCR must only be used to monitor HIV-positive individuals 
before or during antiretroviral therapy (Zhang M et al 2002). It is used in 
conjunction with CD4 counts and general clinical assessments to ascertain when 
therapy should be started. It is also used to help determine the patient's response 
to therapy. Genotyping is used to monitor the development or presence of drug 
resistance in patients before or during therapy. It is also used to assist physicians 
in their choice of antiretroviral drug combinations for the patient (Zhang M etal 
2002), ( Hirsch MS,et al 2003). 
Quantitative PCR should not be used as a diagnostic test for HIV because false 
positives and false negatives can occur in these circumstances. 
2.10. T.Lymphocytes:   
              CD4 and CD8 molecules are T cell surface glycoproteins that are expressed 
on mutually exclusive subsets of mature T cells with distinct patterns of MHC 
restriction (Howcroft et al., 1993).CD4 and CD8 serve as accessory molecules by 
facilitating interaction of T cells with APCs or CTL target cells respectively.  
             The function of CD4 and CD8 are intricately associated with TCR function 
and therefore accessory molecules are often called coreceptoers. Approximatly 
65% per cent of peripheral α B- positive T cells express CD4, and 35 % express 
CD8 (Howcroft et al., 1993). 
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2.10.1. CD4 cells: 
               CD4 cells are the major targets for HIV. Also known as helper T-cells, are 
a type of lymphocyte, which is a white blood cell that plays an important role in 
the immune system. Lymphocytes control the body's ability to recognize and fight 
infections and cancers. CD4 lymphocytes help to identify, attack, and destroy 
specific bacteria, fungi, and other germs that infect the body. In addition, they 
regulate the production of antibodies, and cytokines. CD4 cells are produced in 
bone marrow and differentiated in thymus, then migrates to spleen and lymph 
nodes, they circulate throughout the body in the bloodstream. HIV binds to the 
surface of CD4 cells, enters them, and either reproduces immediately, killing them 
in the process, or remains in a resting state, reproducing when the cell becomes 
active (Lang et al., 1989).  
              The number of CD4 cells in a blood sample, which is called CD4 count, 
ranges from 500 to 1600 cells/µl. The CD4 cell count is a laboratory marker of the 
strength of the immune system. CD4 T lymphocyte subset count is one of the best 
measurements for monitoring disease progression in HIV infected individuals (De 
Wolf,. 1988 Stein,. 1992). 
             The plasma CD4 lymphocyte count (CD4 count, T-helper cell count) has 
been used since the beginning of the HIV epidemic to indicate disease stage, 
although it has some limitations (Hoover et al., 1992; Malone et al., 1990). 
Individual determinations may vary significantly. Identifiable causes of variation 
include time of day, short-term changes in health, and experience of the clinical 
laboratory performing the test. Nevertheless, over many months, the decline in 
CD4 cells reflects progression of untreated HIV disease, and prior to 1996, used 
CD4 counts to indicate disease stage. The CD4 count alone does not always reflect 
the clinical status of an HIV-infected individual; untreated individuals with similar 
CD4 counts may have very different functional status, frequency of opportunistic 
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infections, and constitutional symptoms and signs. Further, the CD4 cell numbers 
reflect only one aspect of immunocompetence. Treatment with potent antiretroviral 
therapy often results in return of CD4 counts to high levels that probably mask 
other immune system defects, thus somewhat complicating staging of disease. To 
understand a patient's disease stage in the era of potent antiretroviral therapy, the 
clinician should consider both the most recent CD4count and the patient's lowest 
past count ("nadir CD4 count"). Even in patients who have responded to 
antiretroviral therapy with markedly increased CD4counts, however, subsequent 
decline of over time indicates continuing progression.   
2.10.2. Function of CD4: 
         Two important function in the activation of CD4 cells: 
1- CD4 serve as cell-cell adhesion molecule, by virtue of it is specific affinity 
for class 11 MHC molecules. The invariant CD4 molecule bind via it is two 
N-terminal Ig-like domains to non polymorphic B2 domain of the class 11 
MHC molecule. 
2-  CD4molecule may transduce signals or facilitate TCR complex mediated 
signal transduction upon binding class 11 MHC molecule there by promoting 
the subsequent functional responses of class restricted T cells 
2.10.3. Function of CD8: 
            The CD8 molecule is thought to have the same two general roles as CD4 
namely in cell to cell adhesion and signal transudation. First CD8 serve as cell to 
cell adhesion molecules by binding to nonpolymorpgic immunoglobulin-like α3 
domain of class 1 MHC molecule there by stabilizing the interaction of class 1 
MHC-restricted T cell (usually a CTL) with a target cell bearing class 1 MHC-
associated antigen. Second the CD8 molecules may tranduce signal or may 
facilitate TCR: CD3-mediated signal transduction upon binding class 1MHC 
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molecules, there by promoting subsequent function responses of class 1-restricted 
T cells.       
2.11. Methods for CD4 &CD8 lymphocyte enumeration: 
             Accurate and reliable measures of CD4 T. lymphocytes are essential for the 
assessment of the immune system of HIV -infected person (Turner et al., 1994; 
Hoover et al., 1992). The pathogenesis of AIDS is largely attributable to the 
decrease in T.lympocytes that bears the CD4 receptors (DeWolf et al., 1988; Smith, 
1990). Progressive depletion of CD4 T.lymphocytes is associated with an increased 
likelihood of clinical complication (Hanson et al., 1995; Stein et al, 1992). 
Consequently, the Public Health Service (PHS) has recommended that CD4 
T.lymphocyte levels be monitored every 3-6 month in all HIV – infected persons 
(CDC, 1992).The measurement of CD4 T. cells levels has been used to establish 
decision points for initiating pneumocystis carinii pneumonia prophylaxis (CDC., 
1995) and antiretroviral therapy (National Institutes of health., 1990) and to 
monitor the efficacy of treatment (Goldman et al., 1996- De Gruttola et al., 1994). 
CD4 T.lymphocyte levels are also used as prognostic indicator in patient who have 
HIV disease (Fahey et al., 1990; CDC, 1994) and recently have been included as 
one of the criteria for initiating prophylaxis for several opportunistic infections that 
are squeal of HIV infection (CDC, 1995; CDC, 1993).Moreover, CD4 
T.lymphocytes levels are a criterion for categorizing HIV –related clinical 
conditions by CDC’s classification system for HIV infection and surveillance case 
definition for AIDS among adults and adolescents(CDC, 1992). 
Other observations made in the era prior to the advent of combination 
therapy also suggest it is likely that nearly all HIV-infected persons will eventually 
lose CD4 lymphocytes and progress to AIDS in the absence of effective treatment. 
For example, in about 10 years of follow-up of 288 men HIV-seropositive at 
baseline in the San Francisco General Hospital Study (1983-1993), only one 
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(0.3%) maintained a CD4 lymphocyte count above 700/µl throughout follow-up 
and nearly all showed some worsening of other laboratory values predictive of 
AIDS, such as anti-p24 antibody levels, .B-2 microglobulin, or neopterin. Most 
HIV-positive persons, even with near-normal CD4 lymphocyte counts, show 
functional lymphocyte abnormalities that suggest their long-term immune 
functioning will be impaired. There are no clearly documented instances of persons 
who appear to have cleared a longstanding HIV infection, although there is a report 
of transient infection in an infant (Berdberg & Raden et al., 1995). 
 CD4T.lymphocytes can be counted by different techniques either automated 
or manually.  
 2.12. Treatment and control: 
Numbers of different antiretroviral agent have been developed. Of these, the 
RT inhibitor AZT has been the most widely used. Major toxicities of AZT include 
neutropenia, anaemia and myopathy. Several other nucleotide analogues that act as 
chain termination in the synthesis of the DNA provirus. Such as DDI didanosine, 
Zalcitabine (ddc) and stavudine (d4T), but they toxicities. Non competitive 
inhibitor of the RT includes nevirapine and delavirdine. In general, all TR 
inhibitors are limited by their low potency, their side effects and the development 
of resistance. Protease inhibitors such as saquinavir have the advantage of being 
able to inhibit HIV replication in cells that are chronically infected (Butera & 
Folks, 1992). AZT delays the development of opportunistic infection and prolongs 
survival. How early to start AZT remains controversial. Most clinical experts 
however, agree on recommending AZT when the CD4 cell count drops below 
500.The development of clinically significant AZT resistance, the development of 
opportunistic infection, and progressive weight loss and constitutional symptoms, 
seem to comprise a good indication for need to change treatment. In USA, 
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recommendations have been issued for the use of AZT in HIV infected pregnant 
women to reduce prenatal transmission. Currently there is no effective vaccine 
available and limited clinical trials are conducted to test candidate vaccines (CDC, 
1994b). 
Immune reconstitution could be found in part of HIV/AIDS patients after 
receiving highly active anti-retroviral therapy (HAART). Its influencing factors are 
very complex. Many factors, such as the demographic factor, stage of HIV disease, 
pattern of therapy, sort of co-infections, baseline of CD; T-cell count, abnormal 
immune activation, related immune phenotype, and virologic factors, all could 
influence the immune reconstitution (Wang  et al.,2009)  
3. Visceral Leishmaniasis in Sudan: 
VL has been reported in Sudan since the beginning of 20th century (Zijlstra 
& Elhassan, 2001). The first case reported in Sudan was described by Neave in 
1904. The patient was a boy aged 8-9 years from Bahr-El Gazal and diagnosed at 
Omdurman Teaching Hospital. The patient was suffering from diarrhoea and 
splenomegaly and that was the second case reported in Africa after the first case 
which was reported in Tunis 1903 by Laveran. The second case reported in Sudan 
was an Egyptian soldier who had contracted the disease in Singa town and died in 
Cairo in 1907 (Cummins, 1908). As a result of a continuous reporting of cases of 
VL, two governmental commissions were set in the period between 1908-1911 to 
investigate the disease in the Eastern and the Blue Nile provinces. One commission 
was headed by (Bousfield 1908-1910) a pathologist of the Welcome Research 
Laboratory. The other one was by two pathologists, (Archibal and Marshal 1911-
1913). 
The commission was closed in October 1913 and it was concluded that VL 
was endemic in the Eastern province particularly Mafaza, Singa, Kassala, Galabat, 
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Gadarif, Sofi and Tomat (Satti, 1958). It was reported that dogs had been the 
naturally infected reservoir (Marchal, 191l). 
Since then, researchers continued investigating different aspects of VL 
between 1931 and 1959, which revealed valuable information in a series of papers 
under the heading: "Studies in Leishmaniasis in Anglo- Egyptian Sudan". They 
studied different aspects of the disease involving vector, transmission and clinical 
presentation as well as treatment (Henderson, 1937; Kirk & Satti, 1940a; Kirk & 
Lewis, 1940, Kirk & Satti, 1947). 
VL occurs in sporadic small outbreaks and sometimes attaining an 
epidemic form in the Upper Nile province and South Fung District of the Bule Nile 
province (Stephanson, 1940; Satti, 1958, 1963a) .A major epidemic took place in 
1988 among displaced southerners from Bentiu, where a lot of people died (El 
Hassan et al., 1993). The dynamics presented in (Figure 1) suggest that Southern 
Sudan is currently between epidemics and provide a warning that cases may rise 
dramatically in coming years. In 2006, a total of 1,117 cases were reported, 65.4% 
of which were primary cases; the remainder were either relapses or cases of post–
kala-azar dermal leishmaniasis (Jan H. Kolaczinski et al., 2008). The WHO 
estimated that at least 400.000 people were killed by the disease and it had been 
well known by natives in Sudan by different name e.g. Seimaih, Dobal, Elsaid 
fever (Thomson, 1911). 
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Figure 27. Total annual number of kala-azar cases in Southern Sudan reported to the World Health Organization, 1989–2006 
 
In Sudan, the disease was found to be endemic in the Eastern Region: 
Kassala, Gadarif, Hawata, Rahad and Dinder River up to River Atbara (E1 Safi et 
al., 2002; Zijalstra & El Hassan, 2001). In the center it encroaches on the Blue Nile 
State and to the south in the Upper Nile province and Equatoria State (Kapoeta). 
Different foci were detected in Darfur, near the Nuba Mountains (Kirk & Lewis, 
1955). 
The disease had been reported in Khartoum province by (Shamsedin 1969) 
and later by (Kadaru 1995), who reported two cases from El Alafon who had never 
left their home. Small outbreaks were reported in El- Khogalab village where it 
affected 22 school children's (Hamza et al., 1976) and Eidumish, in the White Nile 
(El Safi, 1996) as well as Wad zaki near Eldweim in the White Nile State (Kadaru, 
1995). The disease attained seasonal variations, with prepondrance between 
October and February (Henderson, 1937; Kirk, 1939). There was increased 
incidence of transmission during the rainy season which was supposed to be due to 
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humidity and low temperature (Manson & Bahar., 1987). It most commonly affects 
young adults and was common among children in Bentiu in the South. (Henderson, 
1937) Males are more affected than females (Kirk, 1939). It is general a disease of 
low socio-economic classes where malnutrition acts as a provoking factor (Kirk, 
1959; Yousif & WHO, 2001). 
For a considerable time, workers in the field of leishmaniasis in the Sudan 
investigated the possible reservoir hosts (Kirk, 1956; Satti, 1958; Hoogostraal et 
al., 1963). They observed that small outbreaks had occurred among military 
personnel who had been stationed in remote uninhabited lands. In 1963 
Hoogostraal and his group demonstrated natural Leishmania infection in the grass 
rats Arvican niloticus luctuosus, the rodent, Rattus Rattus and Accomys species 
which co-incited with the distribution of P. orientalis in Malakal. Accordingly, 
they concluded that nile grass rats were the possible reservoir hosts of VL. 
Sixel (1987) found massive Leishmania infection in a Jakal, which was 
suggested as a possible reservoir in southern Sudan. Recently a preliminary report 
in two villages (Bandigues & Um Salala), in Eastern Sudan by (Mukhtar, et al 
2000) described the detection of L. donvani antibodies by DAT and ELISA in 
animal's sera such as sheep, cows, dogs, camels and donkeys. In regular 
episemiological studies, which were carried out by (Elsafi, et al., 1997-2000) in 
Barbar el Fugara, a village in Gedarif State (eastern Sudan), they found the parasite 
in lymph node culture of dogs, rodents and donkeys. 
In Sudan the pioneer work of Kirk and his colleagues on the vector showed 
that P. orientalis was the main vector of VL in Sudan (Kirk & Lewis, 1947). It is 
widely distributed in the endemic area of VL, and is found in Kassala, Blue Nile, 
Darfur, Melut, Malakal and Kapoeta (Kirk & Lewis, 1955). P. orientalis was found 
to be naturally infected with leishmania (El Naiem, 1996). The flies rest during the 
day in the cavities of trees in wet seasons and in cracks in the soil during dry 
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seasons (Cheesbrough, 1995). Biting commences immediately after darkness and 
increases about sunrise (Hoogostraal & Dieleuin, 1962). 
PKDL is most commonly reported in India (WHO, 1996). It is known to 
occur in the Sudan during or shortly following treatment (Kirk and Satti, 1940 and 
Satti 1963a). It can even occur without past history of VL (EL-Hassan et al., 1992) 
or as puncture rash (Kirk & Satti., 1940) or as nodular depigmented areas (Kirk & 
Macdonalds, 1940). It affects most commonly the face, limbs, extensor surfaces of 
the arm and trunk.       
 
4. HIV/AIDS in Sudan:  
Years of civil war and limited epidemiological data make it difficult to 
generalize about the status of HIV/AIDS in the Sudan. It is generally agreed that 
the country is in the early stages of a generalized HIV/AIDS epidemic, with an 
almost exclusively heterosexual transmission pattern, and indications of higher 
infection rates in the South than in the North. Internally displaced persons, 
refugees, prison inmates and members of the armed forces are some of the groups 
believed to be particularly vulnerable to HIV infection. In addition, high risk 
groups such as commercial sex workers are known to exist in the country, and 
studies to further understand their risk profile are planned. From a regional 
perspective, the country is very important to the treatment scale up efforts in the 
WHO Eastern Mediterranean Region (EMRO), because 73% of people requiring 
ART in the region have been estimated to reside in Sudan (WHO, 2006). The first 
case of AIDS was reported in 1986, and by December 2006, the adult national 
prevalence was 1.6%, indicating that Sudan is now in generalized epidemic 
(http://www.unaids.org/en/HIV_data/epi2006/default.asp) (Jorge Alvar. 2008) 
The most reliable available indication of the extent of the epidemic is the 
2002 Situation Analysis study conducted in the government-controlled parts of the 
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country (11 out of 16 states in the north and 3 in the south). The study yielded HIV 
prevalence rates ranging from 0.5% for soldiers, 1% for antenatal care attendees, 
truck drivers, and Internally Displaced Persons (IDPs), 2.5% among female tea 
sellers, to 4.4 % among female sex workers. More recently, results of limited 
sentinel surveillance testing conducted during 2004 by SNAP yielded prevalence 
rates of 0.95% (18/1900) among pregnant women, 1.9% (9/465) among 
symptomatic STD patients, and 2.3% (33/1436) among TB patients.  
It needs to be clarified that there have been two prominently cited estimates 
of the HIV sero-prevalence for the general population (1.6% as well as 2.6%), in 
various documents discussing HIV/AIDS in Sudan. However the 1.6% figure 
appears to have been derived from aggregation of the overall HIV positive rate 
among all the samples from the various groups tested during the epidemiological 
component of the 2002 Situation Analysis study (SNAP, 2002). But the 
methodology employed by the study would suggest that it was designed to 
determine sero-prevalence for the various groups studied, rather than the “general 
population prevalence” from the overall positive rate among the samples collected. 
The estimate of 2.6 % was based on a UNAIDS/ WHO modeling for the whole 
country (2003).  
              The limited available data from Southern Sudan suggest relatively higher 
infection rates, compared to the north. Studies have yielded general population 
prevalence rates ranging from 2.7 in Yei (2003) to 7% in Yambio (2000). In the 
city of Juba, (located in the south but administered by the government), 10% of 
female tea sellers (a group some of whose members are believed to engage in 
casual / commercial sex), were found to be HIV positive in 2002. These higher 
rates of infection would suggest that IDPs hailing from the affected areas may have 
higher HIV rates than their host communities, this being made even more likely by 
the disruptions to family cohesion and sexuality norms that being an IDP could 
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cause. Unfortunately this assumption could also reinforce a perception of relative 
safety and inaction for communities in the North of Sudan. It therefore worth 
pointing out that despite citation of the report of one survey yielding of a 5% HIV 
positive rate among IDPs in Khartoum, this level of infection is not supported by 
other data. For instance, the 2002 situation analysis study yielded an IDP HIV 
prevalence of 1%, the same as that obtained for pregnant women in all the states, 
and results of sentinel testing among IDP antenatal mothers in Khartoum, done by 
SNAP and CARE during 2004, yielded a positive rate of 1.6% (11/700), very 
similar to the 1.5% (5/400) for general population pregnant women in the Red Sea 
state, for the same period (SNAP, 2004).  
HIV/AIDS prevalence, based on scarce epidemiological and behavioral 
information, is estimated by UNAIDS to be around 2.3% in the adult population. 
Rates of HIV infection have been estimated by Sudan National AIDS Control 
Programme (SNAP) to be at 1.6 % nationwide. For Southern Sudan, estimates vary 
from 1% to 7.2% with alarming rates among certain population (SNAP, 2006).  
5. Overview of Leishmania/HIV co-infection: 
           Leishmania/HIV co-infection is emerging as an extremely serious, new 
disease and it is increasingly frequent (WHO 2000). There are important clinical, 
diagnostic, chemotherapeutic, epidemiological and economic implications of this 
trend. Although people are often bitten by sandflies infected with Leishmania 
protozoa, most do not develop the disease. However, among persons who are 
immunosuppressed (e.g. as a result of advanced HIV infections, 
immunosuppressive treatment for organ transplants, haematological malignancy, 
auto-immune diseases), cases quickly evolve to a full clinical presentation of 
severe leishmaniasis. 
           AIDS and VL are locked in a vicious circle of mutual reinforcement. On the 
one hand, VL quickly accelerates the onset of AIDS (with opportunistic diseases 
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such as tuberculosis or pneumonia) and shortens the life expectancy of HIV-
infected people. On the other hand, HIV spurs the spread of VL. AIDS increases 
the risk of VL by 100-1000 times in endemic areas. This duo of diseases produces 
cumulative deficiency of the immune response since Leishmania parasites and HIV 
destroy the same cells, exponentially increasing disease severity and consequences. 
The HIV/AIDS pandemic has modified the natural history of leishmaniasis . HIV 
infection increases the risk of developing VL by 100 to 2,320 times in areas of 
endemicity, reduces the likelihood of a therapeutic response, and greatly increases 
the probability of relapse. At the same time, VL promotes the clinical progression 
of HIV disease and the development of AIDS-defining conditions. Both diseases 
exert a synergistic detrimental effect on the cellular immune response because they 
target similar immune cells( Jorge Alvar et al., 2008) 
 
Patients who are coinfected with visceral leishmaniasis and HIV could be a 
reservoir for development and spread of drug-resistant strains (Van Griansven, 
2010)   
 VL is considered a major contributor to a fatal outcome in co-infected patients. 
Lately, however, use of tri therapy, where it is available, has improved the 
Prognosis for Leishmania/HIV cases. Leishmaniasis can be transmitted directly 
person to person through the sharing of needles, as is often the case among 
intravenous drug users. This group is the main population at risk for co-infection.  
  Although cases of co-infection have so far been reported in 33 countries 
worldwide, most of the cases have been notified in south western Europe (Desjeux, 
2001) where up to 70% of all adult cases of VL are related to HIV/AIDS and up to 
9% of all AIDS cases suffer from newly acquired or reactivated VL (Desjeux & 
UNAIDS, 1998).                            
59 
 
Leishmania/HIV co-infections impose specific difficulties 
in terms of diagnosis and treatment. The usual clinical features 
(fever, weight loss, liver and spleen enlargement, inflammation of 
the lymph nodes) are not always present. The clinical diagnosis 
can also be made difficult by associated diseases such as 
cryptosporidium, disseminated cryptococcosis, cytomegalovirus 
infection or mycobacterial infection.  
           The serological diagnosis is falsely negative in 42.6% of 
co-infected patients. HIV-positive patients have difficulty in 
producing antibodies against new infectious agents, especially at a 
late stage or during relapses. Consequently, there is a need to use 
two or more serological tests and antigens freshly prepared in the 
laboratory to increase sensitivity.  
            Although multiple localizations are frequent (blood, skin, 
digestive tract, lungs, central nervous system), parasitological 
diagnosis can be difficult and has to be repeated to orient the 
treatment. Bone marrow aspirate (BMA) remains the safest and 
most sensitive technique, but spleen aspirate and liver biopsy are 
also used. When BMA cannot be performed, the search for 
Leishmania can be conducted in peripheral blood samples.  
              Treatment for co-infected patients is aimed at clinical and 
parasitological cures and prevention of relapses. Unfortunately, in 
such patient treatment failure, relapses due to drug resistance and 
drug toxicity are very common. In south-western Europe, follow-
up studies using pentavalent antimonials, the same first-line drug 
used to treat classic leishmaniasis, show a positive response in 
83% of cases. However, 52% of patients relapse within a period of 
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one month to three years, with the number of relapses ranging 
from one to four.   
           The main alternative drugs include pentamidine, 
amphotericin B and amphotericin B encapsulated in liposomes. 
This encapsulation reduces the occurrence of side-effects, but 
relapses still occur and the drug remains extremely expensive.  
          Leishmania/HIV co-infections can lead to epidemiological 
changes which modify the traditional patterns of zoonotic VL. Co-
infected patients harbour a high number of Leishmania in their 
blood so there is also a risk of them becoming reservoirs of the 
disease (that is, infective for the sandfly vector) as in 
anthroponotic foci in Bangladesh, India, Nepal and East Africa. 
Consequently, there is an increased risk of future epidemics.  
        Experimentally, sandflies can be infected through a blood 
meal containing a very small quantity of blood from co-infected 
patients. The quantity may be less than the content of a needle. As 
71.1% of co-infected patients in south-western Europe are 
intravenous drug users, transmission of Leishmania has occurred 
through the sharing of syringes in this population group. 
5.1. Global Leishmania/HIV co-infection: 
               Cases of Leishmania /HIV co-infections are being reported more 
frequently in various parts of the world. The first case of leishmaniasis associated 
with HIV infection was reported in 1985 .(Jorge Alvar .et al. 2008) It is anticipated 
that the number of Leishmania /HIV co-infections will continue to rise in the 
coming years and there are indications that cases are no longer restricted to 
endemicareas.  
The overlapping geographical distribution of VL and AIDS is increasing due to 
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two main factors: the spread of the AIDS pandemic in suburban and rural areas of 
the world, and the simultaneous spread of VL from rural to suburban area.   
            Leishmania/HIV co-infections are considered a real threat, especially in 
south-western Europe. Of the first 1 700 cases of co-infection which have been 
reported to the World Health Organization (WHO) from 33 countries worldwide 
up to 1998, 1 440 cases were from the region: Spain (835); Italy (229); France 
(259); and Portugal (117). Of 965 cases retrospectively analyzed, 83.2% were 
males, 85.7% were young adults (20-40 years old) and 71.1% were intravenous 
drugs users.        
              Most co-infections in the Americas are reported in Brazil, where the 
incidence of AIDS has risen from 0.8 cases per 100 000 inhabitants in 1986 to 10.5 
cases per 100 000 inhabitants in 1997. As HIV transmission has spread into rural 
areas, VL has simultaneously become more urbanized--especially in north-eastern 
Brazil--increasing the risk of overlapping infection.  
 
5.2. Leishmania /HIV Co infection in Africa: 
The number of cases of Leishmania/HIV co-infection is expected to rise in 
Africa owing to the simultaneous spread of the two infectious diseases and their 
increasingly overlapping geographical distribution, complicated by mass 
migration, displacement, civil unrest, and war.  
         In general, the reported cases of Leishmania/HIV co-infection in Africa are a 
very modest estimation and would substantially increase if active surveillance were 
implemented throughout the continent. Ethiopia has a well-organized system of 
detection, management and reporting of co-infection. Kenya and Sudan began 
surveillance in 1998 and Morocco has also established a surveillance centre. 
        In East Africa, cases of Leishmania/HIV co-infections have been reported in 
Djibouti (10), Ethiopia (74), Kenya (15), Malawi (1) and Sudan (3). West Africa 
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has no official surveillance system yet, but several cases have been reported: 
Cameroon (1), Guinea Bissau (1), Mali (4) and Senegal (2). In North Africa, cases 
have been reported in Algeria (20) and Morocco (4).   
5.3. Leishmania /HIV Co infection in Sudan: 
In view of the fact that both VL and HIV infections are increasing in the 
Sudan particularly in eastern and southern states where both infections overlap, VL 
casers co-infected with HIV may be found (Elsafi et al 1998-1999). 
Up to 1998, only three cases of coinfection had been 
identified. Since then, the reported prevalence in hospital-based 
studies was 5% (3/60) in Khartoum between 1998 and1999, 9.4 % 
(5/53) in Khartoum in 2002, and 8.1% (3/37) and 3.6 % (3/84), 
respectively, in 2002 and 2003 in Gedaref state. Because of the 
spread of both VL and HIV, an increase in the prevalence of 
coinfection is expected. Most coinfected cases present with typical 
manifestations of VL (WHO, 2007).  
In Sudan 1990-1998 only 3cases of leishmania and HIV co-infection were 
reported (Poredes et al 1997). The numbers are expected to rise owing to factors 
such as increasing mass migration, displacement, civil unrest, war and sex work. 
Elsafi et al (1997) have confirmed the prevalence of leishmania/HIV co-
infection in Sudan. 6.5% of VL cases have been found to be co-infected with HIV. 
Most (75%) HIV co-infected cases come from eastern and southern Sudan. This is 
in accordance with the fact that these are the two most affected areas in the country 
with regards to both VL (MSF-Holland Report, 1996-1999) and HIV infection 
(SNAP Report 1997-1998). 
Generally HIV co-infected VL cases presented with clinical features typical 
of VL although splenomegaly was found only in 75% of the cases (Elsafi et al 
1998-1999). 
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In clinicoepidemiological and serological studies of Leishmania /HIV Co- 
infection in Sudan, which carried out by (Elsafi et al 1999-2005) to determine the 
prevalence of HIV infection among patients with VL and to investigate the clinical, 
epidemiological and serological features of coinfected cases in the Sudan, three 
series of confirmed VL cases( total 150 patients were studied, 5%(3/60), 9.4(5/53) 
and 8.1(3/37) of the VL in the three studied series, respectively, were positive for 
HIV. In addition, HIV infection was confirmed in 5 serologicaly confirmed VL 
cases bringing the total of co-infected cases to 15. Two other co-infected patients 
(one parasitologicaly and one serologicaly confirmed) had been detected prior to 
the study period. The 17 co-infected cases included 14 males and 3 females. Their 
age ranged rom 15 to 51 years; 9 were married and 8 were single. Three of them 
presented with relapse and the rest had newly acquired VL. They included 4 
farmers, 4 labourers, one soldier, one student, two house wifes, one merchant and 
the others were civil servants. They belonged to different tribes including Nuba, 
Nuier, Barno, Tama, Masalit, Hawsa, Dago and Nubian. Most of the cases came 
from eastern and southern Sudan, others came from western, central and northen 
parts of the country and two cases came from Ethiopia. The results of risk factors 
for HIV infection in the second series showed that two cases reported illegal sexual 
contact, one had blood transfusion, and one had STD. None of them was 
intravenous drug user and all of them were resident in or had a history of travel to a 
VL endemic area. All the cases complained of fever and fatigue. Other symptoms 
included loss of weight (88%), abdominal pain (71%), couh (59%), anorexia 
(59%), diarhoea (35%) and epistaxis (29%). The clinical signs included pallor 
(82%), splenomegaly (76%), hepatomegaly (65%), lymhpadenopathy (59%), chest 
signs (35%), oral candidiasis (29%), skin lesions (24%) and jaundice (18%). 
Laboratory result showed that all the o-infected patients were anemic; three of 
them had hypochromic microcytic anemia. The TWBCs count was< 2000 in two 
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cases, between 2000-5000 in two cases and >5000 in one case. A comparison of 
series of clinical and epidemiological variables between HIV+ve (5) and HIV –ve 
(48) confirmed VL cases showed that the absence of splenomegaly (P= 0.002), 
lymphadenopathy (P= 0.024), the presence of epistaxis (P= 0.018), and abdominal 
pain (P= 0.018) were significantly more observed in co-infected cases. However, 
no significant difference relating to possible risk factors was observed between the 
two groups.  
In addition, the performance of serological tests (IFAT, ELISA, WB) and 
Katex in the diagnosis of VL in 12 parasitologically and/ or serologically (DAT) 
confirmed patients co-infected with HIV was assessed. Parasitological 
confirmation was obtained in 50% (6/12) of the cases. The DAT was positive in 
67%, IFAT in 91% and both the ELISA and WB were positive in all cases. With 
the exception of one smear negative patient, the Katex was positive in all (7) the 
cases; the test was strongly positive in 5 patients.  
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Justification & Objectives 
 
1.6. Justification: 
VL is a major health problem and has been reported in Sudan since the 
beginning of 20th century (Zijlstra & Elhassan, 2001).  
The first case of HIV infection in Sudan was reported in 1987 in a 
hemophilic boy. Since then infection increased and AIDS become a serious health 
problem (Hashim et al., 1998) 
          An emerging health problem is the increasing occurrence of VL/HIV co-
infection. In view of the fact that both VL and HIV infections are increasing in the 
Sudan, VL cases co infected with HIV may be found. Leishmaniasis acts also as an 
endemic disease which has a high mortality and morbidity rate in Sudan.  
          As the disease is a reticulo-endotheliosis and the parasite sequestrates in 
many visceral organs such as bone marrow, liver, spleen and lymph nodes so, the 
infiltration of these organs may affect their functions. Since these organs are the 
most vital, loss of function leads to other serious complications, so the study of 
biochemical parameters may be considered indicator for stage of disease severity 
and guide for intervention. 
1.7. Objectives: 
General Objective: 
- To confirm the prevalence of Leishmania/HIV co-infection in Sudan.  
Specific Objectives: 
- To measure renal and liver profiles among Sudanese VL\HIV co-infected 
patients. 
-  To correlate CD4 cells count with renal and liver profiles. 
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II. Materials & Methods 
2.1: Study area:  
         The present study was conducted at Tabarak-Allah Rural Hospital in Gedarif 
state, Eastern Sudan; the area is recognized as highly endemic for VL (Dereure et 
al., 2003). Tabarak-Allah  village is located about 100 Km from Gedarif town ; it is 
surrounded by other villages including Barbar, Birkat Nowrin and Mashroua Firsan 
from which VL suspects are referred. The hospital is specialized in Kala-azar 
diagnosis and treatment and is under the responsibility of the Ministry of Health, 
Gedarif State. It has a laboratory equipped with one light Microscope (Olympus 
CH2), Refrigerator, Centrifuge, Water bath, Geimsa stains and all necessary 
glassware. The laboratory is capable of carrying out important routine 
investigations for most of the important endemic diseases such as malaria, typhoid, 
leishmaniasis and tuberculosis. The laboratory staff consists of one technician, two 
laboratory assistants and a laboratory attendant. The other hospital staff includes   
one doctor, two medical assistants, nurses, midwives and a nutritionist. 
  The other site used for the recruitment of cases in this study was Al- Azaza 
Centre , Sinnar State, an area which is also recognized as endemic for VL( EL 
Hassan et al. ,1995).It is  located about 200 Km from Aldindir town and  is 
surrounded by other villages including Nor Algalil and Um bagara  from which VL 
suspects are referred. The Medical center is specialized in Kala-azar diagnosis and 
treatment and is under the responsibility of the Ministry of Health, Sinnar State. It 
has a laboratory equipped with one light Microscope (Olympus CH2), 
Refrigerator, Centrifuge, Water bath, Geimsa stains and all necessary glassware. 
The laboratory is capable of carrying out important routine investigations for most 
of the important endemic diseases such as malaria, typhoid, leishmaniasis and 
tuberculosis. Its laboratory staff they are one technician, one laboratory assistant 
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and a laboratory attendant. The other staff includes a medical officer, two medical 
assistants and nurses. 
2.2 Study subjects  
The study subjects included VL cases and VL cases that are found to be co-
infected with HIV in addition to confirmed HIV seropositive individuals. 
a. VL cases: 
VL clinically suspects who attended Tabarak-Allah Rural Hospital and Al-
azaza Health Center between April 2008-April 2010 were recruited for the study. 
The criteria for clinical selection were based on the presence of fever for two 
weeks or more, splenomegaly and/or lymphadenopathy after the exclusion of 
malaria.  
b. HIV positive individuals 
All HIV seropositive individuals who had been referred to VCT Centre 
(Gedarif Teaching Hospital) between March and April, 2010 were enrolled in this 
study. 
c. VL/ HIV co infected cases  
This group was identified by HIV testing of all confirmed (parasitologically 
and/or serologically) VL cases. All confirmed VL cases that were found to be   
positive for HIV were included in this study group. 
2.3 Study Design 
          This study is a descriptive study. An eligible clinical suspect was duly 
informed about the objectives and procedures of the study. In case he/she agrees to 
participate, a consent form is signed, before the patient is enrolled in the study.  
In addition, a cross sectional study was done to determine the biochemical 
parameters in known seropositive HIV individuals.  
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2.4 Sample size 
 A total of 99 VL confirmed cases were enrolled in the present study. In 
addition 30 HIV seropositive individuals were recruited from Al Gadarif Teaching 
Hospital). 
 
2.5 Ethical considerations 
The consent of VL cases was obtained for all the study subjects. They were 
invited to be included in the study and informed about the objectives and 
procedures of the study. In case he/she agreed to participate, an informed consent 
form (ICF) was signed before the subject was enrolled in the study.  
2.6 Recruitment of study subjects 
         A coded enrollment number was given for each enrolled patient. The 
personal, epidemiological and clinical data of each VL suspect were collected 
using a standard form. Each patient was examined by the clinician in charge and 
the clinical information was recorded in the Clinical Report Form (CRF).   
2.7 Collection of Samples 
From each enrolled VL suspect, the following samples were collected: 
lymph node and/or bone marrow aspirates, venous blood and urine, for 
parasitological, serological, biochemical and immunological tests respectively. 
Each blood sample was divided into two parts: one part was collected in EDTA 
anti coagulant containers for molecular study; the rest of sample was drawn in 
plain containers, left over night at R.T and centrifuged at 3200 rpm for three 
minutes. Sera were collected in 1.5 ml eppindorf tubes and frozen at (-20c) for 
performance of DAT and HIV screening. Urine samples were collected from all 
VL suspects in sterile containers at the time of diagnosis for the detection of 
leishmania urinary antigen. 
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2.8 Parasitological study 
A. Lymph node aspiration: 
 The diagnosis of VL was confirmed by the demonstration of amastigotes in 
Geimsa stained smear of lymph node aspirate of VL suspects. Specimens (n/157) 
from inguinal lymph node of VL suspects were collected. Slides were cleaned with 
gauze and labeled with patient name and laboratory number. The patient was rested 
on his/ her back with the legs stretched out. The skin over the inguinal gland was 
disinfected with 70% alcohol and then allowed to dry. The gland was held between 
thumb and index finger of the left hand. A 21 G sterile needle was inserted in the 
center of the gland at a right angle to the skin, and the gland was squeezed with the 
left hand while the needle rotated. The fluid then came up through the needle, 
needle was rapidly drawn. The piston of the syringe was drawn back and the 
needle containing lymph node aspirate was attached. After the fluid was 
discharged on the slide it was quickly mixed, left to dry, fixed with methanol and 
stained with Geimsa. It was then examined for amastigotes under the microscope 
using X100 oil immersion (Evans, 1989; WHO, 1996). 
B. Bone marrow: 
A bone marrow aspiration was carried out by the medical officer in charge. 
The patient was asked to lie on his or her abdomen (prone position) or on his/her 
side (lateral decubitus position) Bain BJ et al (2005). The skin is cleaned, and a 
local anesthetic such as lidocaine was injected to numb the area. Patients may also 
be pretreated with analgesics and/or anti-anxiety medications, although this is not a 
routine practice. 
Typically, the aspirate was performed first. An aspirate needle was inserted 
through the skin until it abuts the bone. Then, with a twisting motion, the needle 
was advanced through the bony cortex (the hard outer layer of the bone) and into 
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the marrow cavity. Once the needle was in the marrow cavity, a syringe was 
attached and used to aspirate ("suck out") liquid bone marrow. A twisting motion 
was performed during the aspiration to avoid excess content of blood in the 
sample, which might be the case if an excessively large sample from one single 
point is taken. 
Subsequently, the biopsy is performed if indicated. A different, larger trephine 
needle was inserted and anchored in the bony cortex. The needle was then 
advanced with a twisting motion and rotated to obtain a solid piece of bone 
marrow. This piece was then removed along with the needle. The entire procedure, 
once preparation was completed, typically takes 10–15 minutes. 
If several samples were taken, the needle was removed between the samples to 
avoid blood coagulation (Bain BJ et al 2005). 
2.9 Serological Tests 
The DAT was performed for the demonstration of specific anti leishmania 
antibodies. In addition, the urine latex agglutination test for the detection of 
Leishmania antigen was carried out .Furthermore, the rK39 strip test was carried 
out for the detection of specific anti leishmania antibodies in serum. 
2.9.1 Direct agglutination Test  
A. Performance of DAT 
All the collected sera from the parasitologically confirmed or Suspects VL 
patients were tested with the DAT as described by Harith et al,( 1995). 
 . Two fold serial dilution of serum in 0.9 %( wt/vol) NaCl with 2%( wt/vol) 
gelatin and 80% (wt/vol)2ME and urea(0.02%wt/vol) were added to Leishmania 
antigen using micro titration  plates with 96 V shape wells. A DAT titer of 1:≥ 
3200 was reported as a positive result (Harith et al., 1995). 
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B. Reading DAT plates 
         The plate was placed on a white background and the titer was estimated 
compared to a negative control. The titer was the highest dilution that showed 
visible clumping and aggregation in comparison to the negative control (plate). 
The cut of 1:3200 titers seems to be positive. 
2.9.2 Latex Agglutination Test (KATEX) 
A Katex Kit (Kalon Biological, UK) was performed according to Attar, et al 
(2001); the Kit contains Latex beads that have been coated with IgG anti 
leishmania antibodies. 
A. Principle 
The principle of test is based on agglutination of Latex beads that have been 
coated with IgG in presence of leishmania urinary antigen. 
B. Performance 
The test was performed according to Attar et al (2001.) Sufficient sample 
tubes were labeled for each patient to be tested, 250µl to 1000µl of urine sample 
were transferred into sample tubes, then put in a rack, immersed in boiling water 
and heated for 5 minutes. It was, allowed to cool to ambient temperature before 
applying the test. 
        All reagents were brought to room temperature and the bottle of latex was 
shaken well before testing. 50µl of the treated (boiled) urine sample were placed in 
the reaction zone on the glass slide, and then one drop of the well mixed latex was 
added. Both were mixed until they were completely homogeneous and covering 
the whole surface of the reaction zone. The glass slide was rotated and rocked 
consistently for 2 minutes in both clockwise and anti-clockwise directions to 
ensure complete mixing. Then the degree of agglutination was recorded under a 
good stream of daylight.  A positive and negative control was included in each 
patch. 
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C. Interpretation of results 
        Agglutination was interpreted using the cross system as follow: 
++++ Majority of the latex agglutinates and moves to the reaction   area. 
+++   Agglutination resembles chalk dust scattering onto surface. 
++      Clear agglutinated particles were seen against the background of latex. 
+    Agglutination was just visible as compared to the negative control. 
−        No visible agglutination. 
 All the first three grades of agglutination were regarded as positive. 
2.9.3 rK 39 strips 
The test strip membrane (InBios, Seattle, WA, USA) was coated on the 
bottom with a band of rK39 antigen, and on the top with immobilized anti-protein-
A antibody to detect IgG. A protein A-gold conjugate was used as the 
immunochromatographic detection reagent. One drop of serum was placed on the 
absorbent pad at the bottom of the strip, three drops of the test buffer were added to 
the pad, and the mixture was allowed to migrate up the strip by capillary action. 
After 10 min, the appearance of a red upper (control) line indicated the presence of 
IgG and proper test functioning; a red lower line indicated the presence of anti-
rK39 IgG and a positive test result.  
This rK39 test was performed using LEISMANIA Strip Quick Test 
(CYPRESS DIAGNOSTICS).  
2.10 HIV Testing 
a- VL cases 
Sera of all parasitologically/or serologically confirmed VL patients were 
screened for HIV by ELISA (Microlisa HIV). All reactive samples were confirmed 
using another kit (Bio Rad kits) at the National Health Laboratory. 
        Microwell ELISA is a highly sensitive enzyme immunoassay for the detection 
of antibodies and antigens to HIV-1(including subgroup o&c) and HIV-2 in human 
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serum or plasma. The test was performed in accordance with the manufactures 
instructions.  
        Briefly, all controls and samples were diluted in the ratio of 1:4 using 
conjugate 1, and incubated at 37C for 60 minutes. The wells were washed five 
times with working wash solution and were reacted with 100µl of conjugate 2 for 
30 minutes at 25C. After a final wash as described previously, then 80µl of 
working substrate was added to each well and incubated at R.t for 30min in dark. 
Then 100µl of stop solution was added. After incubation for 2 minutes at room 
temperature, then the absorbance was measured at 450nm in Elisa reader.   
        Negative and positive serum control samples were included for each patch. 
The cutoff   value was calculated as follow:  
Cut off value=NCX+0.2.  
Test specimens with absorbance value greater than or equal to the cut off 
value were reactive by Microlisa-HIV and vice versa. 
b- HIV seropositive individuals 
The diagnosis of HIV infection had been confirmed in all the HIV 
seropositive individuals who were included in the present study from the VCT 
centers. The laboratory diagnosis for those individuals was performed at VCT in 
the hospital and included the following:  screening with rapid test and ELISA in 
addition to confirmation by another kit of third generation of ELISA.      
2.11 Biochemical Studies 
Renal and liver profile was done for 99 VL confirmed patients and 30 HIV 
seropositive individuals.  
2.11.1 Liver profile 
a. Serum bilirubin (Total & Direct) measurement 
Was measured by colorimetry using corning 252 colorimeter and making of 
the fact that absorbance is proportional to the concentration of the analyte in the 
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sample. We add one ml of sulphanilic acid(Total) to the tube of the test total and 
also 1ml of  sulphanilic acid(Direct) to the tube of the test direct  then add 50 µl of 
sodium nitrite to each tube of test then we add 100 µl of serum to each tube, 
incubate for 5 minutes at room temperature, and read the color developed at 520 
nm using the colorimeter. For indirect bilirubin we subtract direct from total to get 
it. (Jandarasik and Groff method).      
b. Serum albumin measurement 
We add 10 µl sample to one ml of bromocresol green reagent, incubate for 
10 minutes at 37C which converted to green colored compound that measured 
colormeterically at 580 nm.(BCG method). 
c. Serum Total protein measurement  
We add 25µl of sample to 2ml of biuret reagent, after incubation for 10 
minutes at room temperature colored compound will be formed which is measured 
colormeterically at 540 nm.(Biuret method). 
d. Serum Aminotransferases (ALT, AST) activity measurement 
Sample was added to substrate, reaction occurs and the rate of reaction is 
monitored kinetically to get the enzyme activity at 340 nm using 
spectrophotometer. 
e. Serum Alkaline phosphatase activity measurement 
Sample was added to substrate, reaction occurs and the rate of reaction is 
monitored kinetically to get the enzyme activity at 340 nm using 
spectrophotometer. 
2.11.2 Renal profile 
a. Blood urea and serum creatinine determination 
  For urea 10µl of serum was added to one ml urease containing reagent, after 
incubation at 37C we add one ml of hypochlorite solution, incubate for 10 minutes 
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at 37C then read the color at 580nm using colorimeter.(Berthlots enzymatic 
method).  
For creatinine we remove proteins by adding 0.5 ml of DW ,0.5ml 10% 
sodium tungestate, 0.5 ml 2/3N sulphuric acid and 0.5 ml of serum, centrifuge for 
3 minutes  then react the supernatant with alkaline picrate to form color measured 
colormeterically at 520 nm.(Jaff chemical method).  
b. Serum Electrolytes (Na+, K+),Ca+2  determination 
We add 10 µl of sample to one ml orthocresolphthalen reagent, after 
incubation at 37C for 5 minutes Calcium will react with the reagent to form color 
compound that measured colormeterically at 580.(Cresolphthalien method). 
0.2 ml of serum /plasma was taken and added to  19.8 ml of deionized water, 
the diluted  sample was  aspirated with the flame photometer,  Na+ ,K+ burned 
with propane gas are excited and gain energy then they loss this energy in a form 
of light which measured by photometric mode.(Flame emission photometer).  
c. Serum Uric acid determination  
We add 25 µl of serum to one ml of uricase containing reagent, incubate for 
10 minutes at 37C then read the color at 520 nm by photometer which is directly 
proportional to the concentration.(Uricase enzymatic Method). 
2.12. Statistical Methods and Data Analysis 
The analysis of the result was done manually, using statistical T.Test, chi-
square and correlation tests. The test was considered as significant when the P. 
value < 0.05. Further, the data was processed and formulated into tables and 
figures using the Microsoft Excel Computer Program. 
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III. RESULTS 
3.1. VL patients: 
 3.1.1. Epidemiological, clinical and diagnostic results:   
     During this study157 suspects with VL were admitted to Tabarak Allah kalazar 
center in Gadarif State (137 suspects) and Al-azaza center in Sinnar State(20 
suspects). 99 patients were confirmed parasitologically and serologically. There 
were 57(57.6%) males and 42(42.4%) females, their ages ranged from 2-75 years 
(mean of ages was 16 years), 75 patients (75.8%) were less than 20 years old and 
24 patients (24.2%) were more than 20 years old. All patients presented with a 
history of fever, usually for two weeks or more, splenomegaly and 
lymphadenopathy. Other symptoms included abdominal distention (65%), weight 
loss (85%), anorexia (55%), epistaxis (45%), diarrhea (40%), and cough (60%), 
(Table: 1). 35(35.8%) persons were masalit,5(5.4%) Tama, 2(2.3%) 
Dago,10(10.9%) Zabarma,1(1.1%) Tera, 2(2.2%) Salhab, 5(5.4%)Gemir, 1(1.1%) 
Bani mora, 4(4.3%) Bani amir, 4(4.3%) Foor, 9(9.8%) Hawsa, 1 (1.1%) Ethiopian, 
5(5.4%) Bargo, 1(1.1%) Aranga, 2(2.2%) Maratia, 3(3.3%) Falata and 2(2.2%) 
Noba, (Table: 2). 
3.1.2. Renal and liver profiles:- 
      Of the 99 confirmed VL cases, jaundice was detected in   Nine (9.1%), 
elevated AST activity in 85(85.9%), elevated ALT 19(19.2%), elevated ALP in 
55(556%).  Low albumin level in 78(78.8%), hyperprotienamia in 40 (40.4%), 
Azotamia in 7 (7.3%), hypocalcaemia in 48 (48.5%), hyponatraemia in 89(89.9%), 
hypokalaemia in 29(29.3%) and hyperkalaemia in 11(11.1%) (Table: 3). Two 
(2.4%) patients had renal failure.  
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(Table .1):  Clinical Features of parasitologically and serologically confirmed 
VL patients. 
Symptoms/Signs Percentage 
Fever 100 % 
Loss of Weight 85% 
Abdominal 
Distention  
65 % 
Cough  65 % 
Anorexia 55% 
Epistaxis 45 % 
Diarrhea 40 %
Vomiting 15% 
Splenomegaly 100 % 
Hepatomegaly 45 %
Lymphadenopathy 100 % 
Pallor 80 % 
Jaundice 9.1 % 
 
(Table .2):  Tribe Distribution of parasitologically and serologically confirmed 
VL patients. 
 
Tribe Number of patients 
Masalit 35(38%) 
Tama  5 (5.4%) 
Dago 2 (2.2%) 
Zabarma 10 (10.9%) 
Tera  1 (1.1%) 
Salhab 2 (2.2%) 
Gemir 5(5.4%) 
Bani mora  1(1.1%) 
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Bani Amir 4(4.3%) 
Foor 4(4.3%) 
Hawsa 9(9.8%) 
Ethiopian 1 (1.1%) 
Bargo 5 (5.4%) 
Aranga 1 (1.1%) 
Maratia 2( 2.2%) 
Falata 3 (3.3%) 
Noba 2 (2.2%) 
 
(Table .3):  Renal and liver profiles of parasitologically and serologically 
confirmed VL patients. 
Parameter Number of patients  
Bilirubin more than 1.0 mg/dl 9(9.1%) 
AST more than 42 U/L 85 (85.9%) 
ALT more than 42 U/L 19 (129.%) 
ALP more than 113U/L 55 (55.6%) 
Total protein more than8.1 g/dl 40 (40.4%) 
Total protein Less than6.0g/dl 2 (2%) 
Albumin Less than3.5g/dl 78(78.8%) 
Sodium less than 135 mmol/l 89(89.9%) 
Potassium less than 3.5 mmol/l 29(29.3%) 
Potassium More than 5.1mmol/l 11(11.1%) 
Calcium less than 8.0 mg/dl 48(48.5%) 
Urea more than 50mg/dl 9(9.1%) 
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Figure.2: Sex distribution of confirmed VL patients 
 
 
 
 
 
 
 
 
 
 
 
Fig: 3 Frequency distribution of T.Bilirubin level in confirmed VL Patients 
 
 
Normal Values: (Up to 1 mg/dl) 
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Fig:4 Frequency distribution of AST level in confirmed VL Patients  
 
 
Normal Values: (Up to 40 IU/L) 
 
Fig: 5 Frequency distribution of ALT level in confirmed VL Patients  
 
 
Normal Values: (Up to  40 IU/L 
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Fig: 6 Frequency distribution of ALP level in confirmed VL Patients  
 
 
 
 
Normal Values: (Up to 113 IU/L) 
 
Fig: 7 Frequency distribution of T.Protien level in confirmed VL Patients  
 
 
Normal Values: (6.0 -   8.0 g/dl) 
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Fig: 8 Frequency distribution of Albumin level in confirmed VL Patients  
 
 
Normal Values: (3.5 - 5.0 g/dl) 
 
Fig: 9 Frequency distribution of  Urea level in confirmed VL Patients  
 
 
Normal Values: (10 - 50 mg/dl) 
 
 
84 
 
Fig: 10 Frequency distribution of Creatinine level in confirmed VL Patients  
 
Normal Values: (0.4 - 1.4 mg/dl) 
Fig: 11 Frequency distribution of Calcium level in confirmed VL Patients  
 
Normal Values: (8.1 -   10.4 mg/dl) 
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Fig: 12 Frequency distribution of Sodium level in confirmed VL Patients  
 
Normal Values: (135 - 150 mmol/l) 
 
Fig: 13 Frequency distribution of Potassium level in confirmed VL Patients  
 
 
 
Normal Values: (3.5 - 5.5 mmol/l) 
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3.2. VL/HIV co-infected patients:  
3.2.1. Epidemiological, clinical and diagnostic results:   
        Seven (7.1%) out of 99 parasitologically and serologically confirmed VL 
cases were co-infected with HIV. Their age ranged from 13- 26 years (mean 22 
years); the prevalence of HIV among adult VL patients (age of more than 16 years) 
was 16.7% (6/36), (figure: 14), (figure: 15). All patients showed fever, 
splenomegaly and lymphadenopathy. One (14.3%) patient was Masalit, 1(14.3%) 
Tama, 2(28.6%) Dago, 1(14.3%) Zabarma, 1(14.3%) Hawsa and 1(14.3%) was 
Noba.  .  
3.2.2. Renal and liver profiles of HIV/VL co-infected patients: 
 One (14.3%) out of 7 HIV/ VL co-infected cases had elevated ALT, 
7(100%) elevated AST, 6(85.7%) elevated ALP activity, 2(28.6%) 
hyperprotienamia, 5(71.4%) hypoalbuminaemia, 3(42.9%) hypocalcaemia, 
7(100%) hyponatraemia, 2(28.6%) hypokalamia and 1(14.3%) hyperkalaemia 
(Table: 4).  
 
(Table .4):  Renal and liver profiles of HIV/VL co-infected patients. 
Pt 
No. 
Sex  Age 
/Year  T.BIL  D.BIL  ALT  AST  ALP  T.P  ALB  UREA  CREAT  CA  Na 
K 
 
1 M 25  0.8  0.19  20  79  129  8.51  2.6  18  0.7  8.1  120  3.5 
2 M 18  o.8  0.34  34  290  145  8.09  3.7  30  0.6  9.2  126  3.4 
3 F 24  0.8  0.26  31  112  192  7.25  3.5  25  0.6  7.4  130  5.2 
4 M 13 0.4  0.21  29  98  127  6.22  3.3  25  0.6  7  114  4.1 
5 F 17 0.5  0.24  156  230  110  6.81  3.1  39  1.2  7.9  114  3.9 
6 M 18  0.6  0.25  13  67  260  7.37  3.3  26  0.7  8.3  116  3.7 
7 M 26  0.5  0.15  21  90  137  8.03  3.6  22  0.6  8.7  130  3.9 
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Fig: 14 Prevalence of HIV among VL patients. 
 
 
 
 
 
 
 
Fig: 15 Prevalence of HIV among adults VL patients. 
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3.3. HIV seropositive individuals: 
3.3.1. Epidemiological, clinical and diagnostic results:   
A total of 30 previously diagnosed HIV seropositive individual’s who had 
been referred to VCT Centre at AlGadarif Teaching Hospital for ART were 
included in this study. 23 (76.7%) of them were males, and 7 (23.3%) were 
females. Their age ranged between 30 and 54 years (mean of age was 40 years). 
Three (10%) out of them had DAT significant titer for VL, and 3(10%) had border 
line titer. 6(20%) were Masalit,1(3.3%) Tama, 1(3.3%) Zabarma,1(3.3%) Gemir, 
1(3.3%) Bani Mora, 4(13.3%) Bani Amir, 2(6.7%) Foor, 3(10%) Ethiopian, 
1(3.3%) Bargo, 1(3.3%) Falata, 2(6.7%) Noba, 1(3.3%) Araki, 1(3.3%) Kawahla, 
1(3.3%) Habania, 1(3.3%) Dianka, 1(3.3%)Gawamaa, 1(3.3%) Sholok and 
1(3.3%) Gaali. (Table: 5). 
 3.3.2. Renal and liver profiles:- 
       Three (10%) out of the 30 studied HIV positive individuals were 
jaundiced,12(40%) with elevated ALT,11(36.7%) with elevated AST , 11(36.7%) 
with elevated ALP, 6(20%) with hyperprotiemaemia,3(10%)with  
hypoprotienamia, 19(63.3%)with  hypoalbuminaemia, 3(10%) with Azotamia, 
16(60%) with hyponatraemia, 2(6.7%) with hyperkalaemia, 10(33.3%) with 
hypokalamia, 13(43.3%) with hyperuricaemia , 1(3.3%) with hypouricaemia 
,16(53.3%)  with hypocalcaemia  and   one (3.3%) had renal failure (Table:6 ). 
3.3.3. CD4: 
CD4 T.cells counts were done by VCT center personnel for 30 HIV 
seropositive individuals during ART using flowcytometry. 18(60%) of the cases 
had CD4 count < 200 cell/ µl, 10(33.3%) had CD4 between 200- 500 cell/ µl, and 
2(6.7%) had CD4 > 500 cell/ µl (Table: 7). 
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(Table .5):  Tribe Distribution of HIV seropositive Individuals. 
 
Tribe Number of patients 
Masalit 6(20%) 
Tama  1 (3.3%) 
Zabarma 1 (3.3%) 
Gemir 1(3.3%) 
Bani mora  1(3.3%) 
Bani Amir 4(13.3%) 
Foor 2(6.7%) 
Ethiopian 3 (10%) 
Falata 1(3.3%) 
Bargo 1(3.3%) 
Noba 2(6.7%) 
Araki 1 (3.3%) 
Kawahla 1 (3.3%) 
Habania 1 (3.3%) 
Dainka 1( 3.3%) 
Gawamaa 1 (3.3%) 
Sholok 1 (3.3%) 
Gaali 1 (3.3%) 
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(Table .6): Renal and liver profiles of HIV seropositive individuals. 
Parameter Number of patients 
Bilirubin more than 1.0 mg/dl 3(10%) 
AST more than 42 U/L 11 (36.7%) 
ALT more than 42 U/L 12 (40%) 
ALP more than 113U/L 11 (36.7%) 
Total protein more than8.1 g/dl 6 (20%) 
Total protein Less than6.0g/dl 3 (10%) 
Albumin Less than3.5g/dl 19(63.3%) 
Sodium less than 135 mmol/l 18(60%) 
Potassium less than 3.5 mmol/l 10(33.3%) 
Potassium more than 5.1mmol/l 2(6.7%) 
Uric Acid more than 7.1 mg/dl 13(43.3%) 
Uric Acid less than 2.0 mg/dl 1(3.3%) 
Calcium less than 8.0 mg/dl 16(53.3%) 
Urea more than 50 mg/dl  4(13.3%) 
 
 
 
(Table .7): CD4 count in HIV seropositive individuals. 
CD4     cell/ µl Number of patients percentage 
< 200 cell/ µl 18/30 60% 
200-500 cell/ µl 10/30 33.3% 
> 500 cell/ µl 2/30 6.7% 
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Fig: 16 Frequency distribution of T.Bilirubin level in HIV seropositive 
individuals 
 
 
Normal Values: (Up to 1 mg/dl) 
 
Fig: 17 Frequency distribution of ALT level in HIV seropositive individuals 
 
 
Normal Values: (Up to 40 IU/L) 
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Fig: 18 Frequency distribution of AST level in HIV seropositive individuals 
   
Normal Values: (Up to 40 IU/L) 
 
Fig: 19 Frequency distribution of ALP level in HIV seropositive individuals  
 
Normal Values: (Up to 113 IU/L) 
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Fig: 20 Frequency distribution of T.Protien level in HIV seropositive 
individuals 
 
 
Normal Values: (6.0 -   8.0 g/dl) 
 
 
Fig: 21 Frequency distribution of Albumin level in HIV seropositive 
individuals 
 
 
 
Normal Values: (3.5 - 5.0 g/dl) 
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Fig: 22 Frequency distribution of Urea level in HIV seropositive individuals 
 
 
 
Normal Values: (10 - 50 mg/dl) 
 
Fig: 23 Frequency distribution of Creatinine level in HIV seropositive 
individuals  
 
 
Normal Values: (0.4 -   1.4 mg/dl) 
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Fig: 24 Frequency distribution of Calcium level in HIV seropositive 
individuals 
 
 
 
Normal Values: (8.1 -   10.4 mg/dl) 
 
Fig: 25 Frequency distribution of Sodium level in HIV seropositive individuals  
 
 
 
Normal Values: (135   -   150 mmol/l) 
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Fig: 26 Frequency distribution of Potassium level in HIV seropositive 
individuals 
 
 
Normal Values: (3.5 -   5.5 mmol/l) 
 
 
(Table .8): Sex distribution of the three groups in the study population 
 
Group Males Females 
 
VL 
57/99(57.6%) 42/99(42.4%) 
 
VL/HIV 
5/7(71.4%) 2/7(28.6%) 
 
HIV 
23/30(76.7%) 7/30(23.3%) 
 
(Table .9): Age distribution of the three groups in the study population 
 
Group Mean (years) Range/years 
 
VL 
16 2 – 75 
 
VL/HIV 
20 13 – 26 
 
HIV 
40 30 – 54 
97 
 
(Table .10): Mean of the Renal and liver profiles of the three groups in the 
study population. 
Parameter 
 
VL patients 
(mean value) 
VL/HIV co-infected 
(mean value) 
HIV patients 
(mean value) 
T.Bilirubin mg/dl 
 
0.8 0.63 0.9 
D.Bilirubin mg/dl 
 
0.46 0.23 0.38 
ALT U/L 
 
32.2 43.4 66.8 
AST U/L 
 
124 138 62.9 
ALPU/L 
 
135 157 114.7 
T.Protein mg/dl 7.8 7.5 7.5 
Albumin mg/dl 3.2 3.3 3.2 
Urea mg/dl 30 26 34 
Creatinine mg/dl 0.83 0.71 0.99 
Calcium mg/dl 8.2 8.1 8.0 
Sodium mmol/l 127 121 133 
Potassium mmol/l 4.0 4.0 3.9 
 
3.4. Comparison between epidemiological, serological ,renal and liver profiles 
of the three groups of study subjects: 
  For clinical and epidemiological data Chi square test was used to compare 
the difference between the three groups of study subjects (significant difference: 
P.Value less than 0.05) (Tables 11, 12). The T.Test was used to compare the means 
of the different biochemical parameters in the three groups (Significant difference 
P.Value less than 0.05). Significant differences were observed between VL and 
VL/HIV co infected cases in DAT titers, gender, age, ALT, AST, ALP, total 
protein, albumin, and creatinine and sodium levels. In addition, comparison 
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between VL/HIV co infected cases and HIV seropositive individuals showed 
significant differences in DAT titers, gender, age, tribe ,ALT ,AST , total protein , 
albumin, creatinine and sodium levels  .  
(Table .11): Comparison between epidemiological, serological ,renal and liver profiles of 
VL and VL/HIV co infected cases 
Parameter VL patients VL/HIV co-
infected patients 
 P.Value 
DAT Titre 10860.6 
 
7314.3 
 
< 0.05 
Gender 57 males/      
42 females 
5 males/         
2 females 
< 0.05 
Tribe Masaleet Masaleet < 0.05 
Age/Years 16 20 0.00 
T.Bilirubin mg/dl 
 
0.8 0.63 0.94 
D.Bilirubin mg/dl 
 
0.46 0.23 0.63 
ALT U/L 
 
32.2 43.4 < 0.05 
AST U/L 
 
124 138 < 0.05 
ALPU/L 
 
135 157 0.02 
T.Protein mg/dl 
 
7.8 7.5 0.02 
Albumin mg/dl 
 
3.2 3.3 0.003 
Urea mg/dl 
 
30 26 0.4 
Creatinine mg/dl 
 
0.83 0.71 < 0.05 
Calcium mg/dl 
 
8.2 8.1 0.6 
Sodium mmol/l 
 
127 121 0.001 
Potassium mmol/l 4.0 4.0 0.52 
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(Table .12): Comparison between epidemiological, serological,renal and liver 
profiles of VL/HIV co-infected patients and HIV seropositive individuals. 
Parameter VL/HIV co-
infected 
patients 
HIV patients  P.Value 
 
 
DAT Titer 
 
7314.3 2720  0.00 
Gender 5 males/        
2 females 
23 males/       
7 females 
0.04 
Age/ Years 
 
20  40 0.01 
T.Bilirubin mg/dl 
 
0.63 0.9 0.97 
D.Bilirubin mg/dl 
 
0.23 0.38 0.83 
ALT U/L 
 
43.4 66.8 0.02 
AST U/L 
 
138 62.9 0.00 
ALP U/L 
 
157 114.7 0.11 
T.Protein mg/dl 
 
7.5 7.5 0.02 
Albumin mg/dl 
 
3.3 3.2 0.07 
Urea mg/dl 
 
26 34 0.98 
Creatinine mg/dl 
 
0.71 0.99 0.003 
Calcium mg/dl 
 
8.1 8.0 0.67 
Sodium mmol/l 
 
121 133 0.001 
Potassium mmol/l 
 
4.0 3.9 0.52 
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4. Discussion 
4.1 Visceral Leishmaniasis: 
In the present study, a total number of 99 patients with VL were recruited 
from two kalazar centers in Gedarif and Sinnar states where the disease is endemic 
in Sudan since the beginning of 20th century (Zijlstra & Elhassan, 2001). As 
reported earlier   both young and older children were equally affected with females 
being less affected .The clinical features were also similar to those reported by 
previous investigators.  Fever, spleenomegaly and lymphadenopathy were found in 
all patients; other symptoms were present but were less common. 
Investigations of Liver function parameters in the present study showed 
that hyperbilirubinemia, hypoalbuminaemia and an increase in liver enzymes were 
pronounced in the majority of VL patients. Most (85.9%) of the patients had 
elevated AST activity while elevated ALT and ALP were found in 19.2%   and 
55.6% respectively. However, only 9.1% `` patients were found to be jaundiced on 
examination. The majority (78.8%) of patients showed low albumin level and 
40.4% had hyperprotienamia. Our findings are in agreement with previous results 
reported by Mustafa et. al.(1995). However, hypoalbuminaemia can be explained 
by many other contributing factors mainly due to Nutritional habits, economical 
status, malaria and chronic diseases.  
 The laboratory results of the study subjects relating to the renal function 
test s indicated the prevalence of two cases of renal failure that had not been 
detected on clinical examination.  Seven patients showed an increase in urea levels 
without deterioration in other renal function tests.  Hyponatraemia was detected in 
89(89.9%), hypocalcaemia in 48 (48.5%), hypokalamia in 29(29.3%) and 
hyperkalaemia in 11(11.1%). These results are in accordance with another study 
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done by (Daher et al.  2008) that indicated renal dysfunction in VL patients. 
Similar results were also reported by (Pintado et al.  2001). In addition, (Agenor 
Araujo Lima et al.2009) reported on the functional tubular disturbances in Kala-
azar cases. Their results showed that hyponatraemia were found in 94.6%, 
hypokalemia in 26% and hypocalcemia in 32%. Furthermore the renal involvement 
was documented in 15% of VL cases by (Prakash,et. al. 2007). 
4.2 Leishmania/HIV co-infection: 
           The present study confirms that Leishmania/HIV co-infection is an 
emerging health problem in Sudan. The number of cases of Leishmania/HIV co-
infection is expected to rise in the country owing to the simultaneous spread of the 
two infectious diseases and their increasingly overlapping geographical 
distribution, complicated by mass migration, displacement, civil unrest, and war. 
Seven (7.1%) of our patients were co-infected with HIV and VL. This figure is 
higher than was reported in earlier studies (Elsafi et al 1997); this may be 
explained by the fact that most of our VL patients were more than 16 years of age.  
 The parameters of  liver function tests  showed that  1(14.3%)  of  the 7  co 
infected cases had an elevated ALT, 7(100%)  had elevated AST activity, 6(85.7%) 
had elevated ALP activity, 2(28.6%) had hyperprotienamia and  5(71.4%) had 
hypoalbuminaemia. Our results are in agreement with a previous study done in 
Italy by (Rollino et al., 2003). 
The parameters of renal function tests indicated that 3(42.9%) had hypocalcaemia, 
7(100%) had hyponatraemia, 2(28.6%) had hypokalamia and 1(14.3%) had 
hyperkalaemia. Our results contradict the findings that were reported by (Rollino et 
al., 2003) in Italy. We explained that by severity of the disease and may be due to 
latency in the diagnosis of VL because that area was endemic with malaria and 
other chronic diseases had the same clinical symptoms.    
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4.3 HIV/AIDS: 
The parameters of Liver and renal function tests were done for all HIV 
seropositive individuals.  Hypocalcaemia was found in 16(53.3%) ; 3(10%) out of 
30 were jaundiced,12(40%) had elevated ALT,11(36.7%) had elevated AST and 
the same number for ALP,. 6(20%) of the individuals had 
hyperprotiemaemia,3(10%) had hypoprotienamia, 19(63.3%) had 
hypoalbuminaemia and 3(10%) had  Azotamia .  One (3.3%) had renal failure, 
16(60%) had hyponatraemia, 2(6.7%) had hyperkalaemia, 10(33.3%) had 
hypokalamia, 13(43.3%) had hyperuricaemia and 1(3.3%) had hypouricaemia.  
Our results are comparable to the findings reported by Pintado et al., (2001). 
In this study the CD4 count was done for all HIV patients during ART 
using flowcytometry. Our results indicated that the CD4 counts were < 200 cell/µl 
in the majority of patients and it was normal or subnormal in some patients who 
showed clinical improvement. Similar findings were reported in other studies that 
had been carried out in Sudan by (Magzoub et al., 2002) and in other countries by 
(Baker et al., 1998). 
4.4 Comparative results:- 
4.4.1 VL and VL/HIV co-infected patients:- 
  The comparison that was done between the two groups showed significant 
differences in epidemiological data (age and tribe) showed ( P.Value < 0.05) . The   
liver function tests also  showed significant differences in  ALT , ALP ,AST , 
T.Protien and Albumin Levels ( P.Value < 0.05) but there was   no significant 
difference in  T.Bilirubin and D.Bilirubin levels ( P.Value > 0.05). The renal 
function tests relating to Creatinine and Sodium levels, were also significantly 
different between the two groups (P.Value < 0.05). However, there was no 
significant difference in Urea, Calcium and Potassium levels (P.Value > 0.05). 
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This may be due to latency in diagnosis or to the sequestration of the parasite in 
those tissues. 
  
 Finally there are no well planed studies addressing this problem in Sudan 
except liver function tests for VL patient that done by (Mustafa 1995). And also we 
recommend searching more in this area. 
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Conclusions & Recommendations 
 
      Conclusions: 
 
1- Renal dysfunction is pronounced among VL patients, and can be useful for 
monitoring the disease severity and treatment. 
2- Renal and liver profiles are variable among AIDS patients, depending on 
many contributing factors; including viremia, stage of disease, period of 
treatment and co-infection with other diseases.  
3- Renal and liver profiles are variable among VL/HIV co-infected patients, 
also renal dysfunction is pronounced among them. 
4- VL / HIV co-infection is an emerging health problem in the study (7.1%) 
which may be associated with a potential risk for more epidemics. 
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 Recommendations: 
1- The prevalence of Leishmaniasis among confirmed HIV patients is 
recommended to be further investigated using a larger sample size. 
2- The renal and liver profiles should be investigated in VL cases when 
clinically indicated.  
3- VL/HIV co-infection is expected to rise in the coming years, further studies 
are recommended to assess the magnitude of the problem at both hospital 
and community levels. 
4- Development of effective health education program for HIV positive 
individuals in VL endemic areas. 
5- Further research in the area of biochemical changes,CD4,CD8 count and 
parasite of VL,VL/HIV for molecular characterization. 
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